Development of lipid biomarker based diagnostic method for TB research in archaeological samples via HPLC-HRMS by Váradi, Orsolya Anna
Development of lipid biomarker based diagnostic 




Orsolya Anna Váradi 
 
Supervisors: 
Dr. habil György Pálfi, associate professor, head of department 
Dr. András Szekeres, senior research fellow 
 
Doctoral School of Biology 
 
Department of Biological Anthropology and Department of Microbiology 
Faculty of Science and Informatics 











“I believe that anyone who claims to know what's going on will lie about 
the little things too.” 



















1 TABLE OF CONTENTS 
 
1 TABLE OF CONTENTS ............................................................................................... 3 
2 LIST OF ABBREVIATIONS ........................................................................................ 5 
3 INTRODUCTION .......................................................................................................... 8 
3.1 A brief overview of the history of tuberculosis ...................................................... 8 
3.2 The Mycobacterium genus ...................................................................................... 9 
3.3 Clinical significance of the some of the NTM species ......................................... 10 
3.4 Overview of the M. tuberculosis complex ............................................................ 11 
3.5 Phylogenetic relationships within the M. tuberculosis complex .......................... 14 
3.5.1 Phylogeny of human-adapted MTBC members ............................................ 14 
3.5.2 Phylogeny of animal-adapted MTBC members ............................................ 15 
3.5.3 The most common hypothesis regarding the origin of MTBC members ...... 16 
3.6 The mycobacterial cell wall constituents .............................................................. 17 
3.7 The main steps in the pathogenesis in the establishment of tuberculosis ............. 21 
3.7.1 Pulmonary tuberculosis ................................................................................. 23 
3.7.2 Extra-pulmonary tuberculosis........................................................................ 23 
3.8 Molecular biological and analytical methods in the use of ancient TB detection 28 
3.8.1 The development of aDNA techniques for TB diagnosis.............................. 28 
3.8.2 The development of lipid biomarker based techniques for TB diagnosis ..... 29 
3.8.3 Examples of the combined macroscopic, aDNA and lipid biomarker based 
examinations................................................................................................................. 31 
4 AIMS AND OBJECTIVES .......................................................................................... 35 
5 MATERIALS AND METHODS ................................................................................. 37 
5.1 Materials ............................................................................................................... 37 
5.1.1 The used bacterial and human samples ......................................................... 37 




5.1.3 Solvents, chemicals and consumables and equipments used for measurements
 38 
5.2 Methods ................................................................................................................ 39 
5.2.1 Optimisation of the mycolic acid detection method ...................................... 39 
5.2.2 Mycocerosic acid separation and detection by Q-Exactive Plus Orbitrap MS
 43 
6 RESULT AND DISCUSSIONS .................................................................................. 46 
6.1 Optimisation of the mycolic acid detection method ............................................. 46 
6.1.1 Mycolic acid detection by single quadrupole LCMS .................................... 46 
6.1.2 Mycolic acid detection by Q-Exactive Plus Orbitrap MS ............................. 49 
6.1.3 Mycocerosic acid separation and detection by Q-Exactive Plus Orbitrap MS
 66 
7 CONCLUSIONS .......................................................................................................... 80 
8 SUMMARY ................................................................................................................. 83 
9 ÖSSZEFOGLALÓ ....................................................................................................... 88 
10 ACKNOWLEDGEMENTS ..................................................................................... 95 
11 REFERENCES ......................................................................................................... 97 





2 LIST OF ABBREVIATIONS 
ABVI  abnormal blood vessel impression 
ACN  acetonitrile 
AcOH  acetic acid 
AG  arabinogalactane 
APDI  abnormally pronounced digital impression 
CDL  curved desolvation line 
CNS  central nervous system 
CW  cell wall 
DAT  diacyl trehalose 
DFBP  decafluorobenzophenone 
ECD  electron capture detector 
EIC  extracted ion chromatogram 
ESI  electrospray ionisation 
FA  fatty acids 
FIA  flow injection analysis 
FID  flame ionisation 
FLD  fluorescence detector 
GC  gas chromatograph 
GI  granular impression 
GMM  glucose monomycolates 
HIV   immunodeficiency virus  
HPLC  high performance liquid chromatograph 
HPO  hypertrophic pulmonary osteoarthropathy 
IPA  isopropanol 
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LAM  lipoarabinomannan 
LM  lipomannan 
LOS  lipooligosaccharid 
LPSN   List of Prokaryotic names with Standing in Nomenclature 
MA  mycolic acid 
MAC  M. avium complex 
MAF/WAF M. africanum type I, Western-African 
MC  mycocerosic acid 
MDR  multidrog-resistant 
MeOH  methanol 
ML  mycolipenic acid 
MMG  monomycolic glycerols 
MPA  molybdophosphoric acid 
MRCA most recent common ancestor 
MRM  multiple reaction 
MS  mass spectrometer 
MTB  Mycobacterium tuberculosis 
MTBC  Mycobacterium tuberculosis complex 
MTBE  methyl tert-butyl ether 
NI-CI  negative ion chemical ionisation 
NP  normal phase 
NTM  non-tuberculous mycobacteria 
PA  periosteal apposition 
PAT  pentaacyl trehalose 
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PBA  pyrenebutyric acid 
PDIM  phthiocerol dimycocerosate 
PFB  pentafluorobenzyl bromide 
PG  peptidoglycan 
PGL  phenolic glycolipids 
PIM  phosphatidylinositol mannosides 
PNFB  periosteal new bone formation 
PRM  parallel reaction monitoring 
PTFE  polytetrafluoroethylene 
RD  region of difference 
RP  reverse phase 
SGL  sulphated trehalose glycolipid 
SIM  selected ion monitoring 
SNP  single nucleotide polymorphism 
SPE  solid phase extraction 
STB  smooth tubercle bacillus 
TB  Tuberculosis 
TBM  tuberculous meningitis 
TDM  trehalose dimycolate 
TLC  thin layer chromatography 
TLR  Toll-like receptors 
TMM  trehalose monomycolate 
TSA  tuberculostearic acid 
XDR  extensively drug-resistant 
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3  INTRODUCTION 
 
3.1 A brief overview of the history of tuberculosis 
Tuberculosis (TB) is not only an infectious disease, but one of the top 10 causes of death, 
spreading mainly with aerosol transmission (WHO, 2020). This devastating plague has been 
accompanying the history of humankind for several millennia (Gutierrez et al., 2005; Daniel, 
2006; Baker et al., 2015; Barberies, et al., 2017). Early proofs of the recognition of the 
disease can be found among ancient Egyptian artworks dated to 3000 BC, moreover 
morphological and aDNA investigations seems to support the existence of this plague in the 
era (Zink et al., 2003). The first written records of the disease are known from China and 
India (Cave, 1939; Brown, 1941; Robert & Buikstra, 2003; Daniel, 2006; Barberies et al., 
2017). Written notes of the disease can be found also in the Bible referring to TB with the 
name “schachepheth” (Daniel & Daniel 1999; Daniel, 2006; Barberies, et al., 2017). TB was 
well known in the ancient Greece also, Hippocrates called it “phthsis” in Book I, of the 
Epidemics (Daniel, 2006; Barberies, et al., 2017). However, the written sources related to 
TB are sporadic from the middle ages, the scrofula or “King’s evil”, as a new clinical form 
of TB with extra-pulmonary nature, was spreading across Europe in this period (Daniel, 
2006; Barberies et al., 2017; Murray, et al., 2016). Despite of the fact that TB was observed 
for such a long time, and known on many names, the first clear explanation of the 
pathogenesis and an unified concept of both pulmonary and extra-pulmonary TB was not 
described until 1819, when Laennec released his book D’Auscultation Mediate (Duffin, 
1998; Daniel, 2004; Daniel, 2006; Barberies, et al., 2017). The first TB sanatorium was 
established in Görbersdorf, 1859 (Daniel, 2006; Barberies, et al., 2017). The infectious 
nature of TB has been proven not long after, in 1865, by Jean-Antoine Villemin. On March 
24th, 1882 Robert Koch presented his results of identifying the infectious agent of 
tuberculosis, which is also known as Koch-bacillus since then. Nowadays this date is 
commemorated as the world tuberculosis day (Daniel, 2006; WHO, 2020). In the 18th-19th 
century tuberculosis was epidemic in Europe implying an extraordinary burden, especially 
after the middle of the 18th century, as the industrial revolution, poverty, urbanisation and 
squalor created an excellent reservoir for the spread of TB (Bello et al., 1999; Vuorinen, 
1999, Glaziou et al., 2018; Loddenkemper et al., 2018; Roberts, 2020). At the beginning of 
the 18th century 10% of all death cases were TB-related, but by the end of the century it 
reached up to 25% of all death in London (Roberts, 2020). Although, these data should be 
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handled with great care, as the records were taken by not educated people and at least four 
names related or not to TB was used at this time. These names are: consumption, King’s 
Evil, fever and tissick, what referred to different lung diseases, however in other countries 
similar trends were observed (Bello et al., 1999; Vuorinen, 1999). Several scientific 
achievements followed Koch’s discovery in the next decades, such as the tuberculin skin test 
of Pirquet and Mantoux, the development of the BCG vaccine by Albert Calmette and 
Camille Guérin, and the insolation of streptomycin the first anti-tuberculotic drug by Albert 
Schatz, Elizabeth Bugie and Selman Waksman (Daniel, 2006; Barberies et al., 2017). 
Despite of all these and the followed efforts TB is still a relevant worldwide burden (Robert 
& Buikstra, 2003; Gutierrez et al., 2005; Roberts 2020; WHO, 2020;). 
3.2 The Mycobacterium genus  
Mycobacterium is a monophyletic group and it is the only genus of the family 
Mycobacteriaceae within the Actinomycetales order including more than 200 species 
according to the LPSN list (Nouioui et al., 2018; Turenne, 2019; http://www.bacterio.net/ 
mycobacterium.html). Mycobacteria are acid-fast aerobic bacilli, including the members of 
M. tuberculosis complex, M. leprae, and non-tuberculous mycobacteria (NTM) (Turenne, 
2019; van Ingen et al., 2018). For the identification of mycobacteria on the species level, 
16S rRNA gene sequencing is widely used, however, in some cases the usage of alternate 
target is also needed, such as certain housekeeping genes (Tortoli, 2014; CLSI, 2018; 
Nouioui et al., 2018; Turenne, 2019). 
The Mycobacterium leprae is the causative agent of leprosy or Hansen's disease, however, 
the disease in less common cases are caused by its sister taxon, M. lepromatosis. M. leprae 
is an obligate intracellular human pathogen (Serrano-Coll et al., 2018; Blevins et al., 2020; 
Borah et al., 2020). In contrast with M. tuberculosis, M. leprae replicates mainly in Schwann 
cells and endothelial cells (Serrano-Coll et al., 2018; Borah et al., 2020). Leprosy can 
manifest as both disseminated infection and localized infection (Borah et al., 2020). The 
characteristic disease caused by this infectious agent is damaging the skin and the peripheral 
nerve trunk (Serrano-Coll et al., 2018). 
NTM species can be primarily found in soil and water, however some of them are 
opportunistic pathogens, causing infections in humans (e.g. M. kansasii) and animals (e.g. 




3.3 Clinical significance of the some of the NTM species 
Mycobacterium kansasii is a slow growing, highly virulent Mycobacterium species, which 
can be isolated mainly from tap water (Johnston et al., 2017; Bakuła et al., 2018). This 
opportunistic pathogen is causing apical fibro-cavitary lung disease (Bakuła et al., 2018; 
Huang et al., 2020). The caused symptoms and observed histopathology, and images are 
similar to those of tuberculosis, however it requires different drug-treatment, which implies 
the need of fast and prompt identification (Huang et al., 2020). 
Mycobacterium chelonae is a rapidly growing NTM species, which can be isolated from 
natural and tap water, soil and aquatic animals (Akram & Saleh, 2020). In the case of human 
infection M. chelonae usually invades the host through an entering site opened due to 
traumas or human interventions on the skin, such as surgery, resulting a localized skin 
infection in immunocompetent patients, however dissemination can occur in 
immunocompromised individuals (Daley & Griffith, 2010; Akram & Saleh, 2020).  
Mycobacterium gordonae is a slow growing NTM species, which is primarily isolated from 
water and soil (Chen et al., 2017; Chang et al., 2020). It is traditionally considered to have 
only a weak pathogenicity, however infections in both immunocompetent and 
immunocompromised individuals have been reported. 
Mycobacterium avium complex (MAC) includes 12 slow growing Mycobacterial species, 
such as M. avium and M. intracellulare, M. chimaera with the predominance of the former 
two, which are responsible for most of the NTM caused lung diseases (Koh et al., 2017; van 
Ingen et al., 2018; Busatto et al., 2019). MAC is an opportunistic human pathogen group 
with an emerging clinical concern. Beside lung disease, they can cause for example cervical 
lymphadenitis and disseminated infection, mainly affecting immunocompromised 
individuals. 
Mycobacterium abscessus is a rapidly growing Mycobacteria, which can be isolated from 
soil, water and tap water (Mougari et al., 2016; Meir et al., 2017; Osmani et al., 2018). This 
opportunistic pathogen can affect the lungs (most often in individuals already having 
pulmonary disease), the soft tissue and skin, central nervous system (CNS), and has the 
ability to disseminate. The main concerns regarding M. abscessus is that it is mainly 
infecting immunocompromised patients, and being resistant for eradication. 
Mycobacterium fortuitum complex includes rapidly growing Mycobacteria, which can be 
found mainly in soil and water (Okamori et al., 2018; Erber et al., 2020). It has been reported 
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to cause pulmonary disease in patients with underlying lung disease, however in case of 
human infection it mainly manifests as skin and bone/joint infection (Gracia-Cazaña et al., 
2017; Okamori et al., 2018; Erber et al., 2020). Several cases were reported, wherein the 
infection was the result of human interventions, opening infection site on the skin (Gracia-
Cazaña et al., 2017; Erber et al., 2020). 
3.4 Overview of the M. tuberculosis complex 
Tuberculosis can be caused by the members of Mycobacterium tuberculosis complex 
(MTBC). The members of this group can cause illness in humans as well as in several animal 
species (Brites et al., 2018). The complex includes so far 12 genetically closely related 
species/varieties with 99.9% similarity in nucleotide level (Brosch et al., 2002; Brites & 
Gagneux, 2017; Brites et al., 2018; Riojas, et al., 2018). The 12 members are the following: 
M. tuberculosis, M. africanum, “M. canettii”, M. bovis, M. microti, M. pinnipedii, M. orygis, 
M. mungi, M. suricattae, M. caprae, “chimpanzee bacillus”, “dassie bacillus” (Brites et al., 
2018; Riojas et al., 2018). The first three species are specifically human pathogens (Castets 
et al., 1968; Brosch et al., 2002; Niemann et al., 2004; Bañuls et al., 2015). 
Myobacterium tuberculosis (MTB) led to the death of approximately 1.2 million people, 
who were not infected with human immunodeficiency virus (HIV), and further 208000 HIV-
positive people died in MTB infection and approximately 10 million people fell ill with TB 
globally in 2019. The most affected regions are South-East Asia, Africa and the Western 
Pacific (Figure 1) (WHO, 2020). 
 
Figure 1: The estimated TB incidence rates in 2019 according to WHO (WHO, 2020) 
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Although M. tuberculosis is responsible for most of the TB infection cases (Bañuls et al., 
2015), Mycobacterium africanum is the causative agent of half of the human TB cases in 
West Africa (de Jong et al., 2010a). M. africanum can be divided into two subgroups 
(Niemann et al., 2004). Subgroup I is more prevalent in the Western African region, while 
subgroup II is mostly spread in the Eastern African region, also reclassified as the part of M. 
tuberculosis sensu stricto (de Jong et al., 2010a; de Jong et al., 2010b; Nimeann et al., 2004). 
The latter group is also known as “Uganda” genotype (de Jong et al., 2010a). Within the 
Western African subgroup two clusters can be divided: MAF1 (or WAF1), and MAF2 (or 
WAF2) (de Jong et al., 2010a; Parsons et al., 2019). The first group is presenting a deletion 
in Region of Difference (RD) 9, the second group beside the deletion of RD9 has further 
deletions in RD7, RD8, RD10.  
“Mycobacterium canettii”, also known as “smooth tubercle bacillus” (STB) – referring to 
its unusual colony morphology – is isolated mainly in East Africa (Koeck et al., 2011; Supply 
& Brosch, 2017). “M. canettii” is primarily causing opportunistic infections in humans 
(Koeck et al., 2011; Brites et al., 2018). Based on genetic similarities and also on the fact 
that “M. canettii” is capable to cause TB, it is traditionally included in MTBC (Brosch et 
al., 2002; Osman et al., 2016; Bouzid et al., 2017; Brites et al., 2018), however, there is no 
consensus in this matter yet, many studies are noting it as a closely related species (Supply 
et al., 2013; Supply & Brosch, 2017; Gagneux, 2018). To decide this question is not part of 
this dissertation, however “M. canettii” is crucial in the understanding of the evolutionary 
connections within MTBC, therefore this species is going to be discussed as an MTBC 
member in this dissertation. 
Mycobacterium bovis is primarily infecting cattle, but it has a wide host range including 
humans, pets and wild animals (de la Rua-Domenech, 2006, Mandal et al., 2011; Allen, 
2017; Gagneux, 2018). M. bovis is responsible for the 0.5-7.2% of human TB cases mainly 
as milk-borne disease, but other uncommon transmission routes have been already reported 
such as close contact with infected cattle, or transmission among immuno-competent people 
(Blázquez et al., 1997; de la Rua-Domenech, 2006; Brites et al., 2018). 
Mycobacterium caprae was initially described as a subspecies of M. tuberculosis, isolated 
from goats (Aranaz et al., 1999), later it was also known as M. bovis subsp. caprae (Niemann 
et al., 2002), and in 2003 was elevated to an independent species status (Aranaz et al., 2003). 
Since the first isolation from goats, M. caprae infection cases have been diagnosed from a 
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range of other mammals, such as cattle, sheep, boars, deer, wolves, captive elephant, rabbit 
and also humans, mainly in Europe (Cvetnik et al., 2007; Orłowska et al., 2017; Yoshida et 
al., 2018; Dorn-In et al., 2020; Reis et al., 2020; Sevilla et al., 2020).  
Mycobacterium microti has been initially characterized as pathogen of small rodents, voles, 
but later a wider range of hosts has been recognized, including pets, livestock, boars and 
even humans (Cavanagh et al., 2002, Panteix et al., 2010; Pérez de Val et al., 2019). 
However, human TB infection caused by M. microti are considered rare, it can be observed 
even in immunocompetent individuals, in both pulmonary and extra-pulmonary forms 
(Panteix et al., 2010). 
Mycobacterium pinnipedii was first described in the beginning of the 20th century, but it was 
identified as a MTBC member only 90 years later (Roe et al., 2019). Its main hosts are 
pinnipeds, but has been also detected from other marine- and non-marine organisms (Kiers 
et al., 2008; Roe et al., 2019; Macedo et al., 2020). Human infection cases were also 
described, however, they are extremely rare and some of the reports might be questionable 
(Kiers et al., 2008; Zmak et al., 2019; Macedo et al., 2020). 
Mycobacterium orygis, earlier known as “oryx bacilli“, had been distinguished clearly from 
M. bovis in 2005 (Mostowy et al., 2005; Dawson et al., 2012), and was classified into the 
MTBC in 2012 (van Ingen et al., 2012). It can infect a wide range of animals including 
several species of antelopes, gazelles, cow, rhesus monkey as well as even rhinoceros and 
humans (Dawson et al., 2012; van Ingen et al., 2012; Thapa et al., 2016; Marcos et al., 2017). 
Although, TB cases in humans caused by M. orygis can be considered really rare, not only 
animal-to-human transmission was presented, but in one case a human-to-animal 
transmission route was already characterized (Dawson et al., 2012; van Ingen et al., 2012). 
Mycobacterium mungi had been first discovered in Botswana, where it was infecting banded 
mongooses with a high mortality rate (Alexander et al., 2010). In contrast with other MTBC 
members the primary rout of transmission of this pathogen is not respiratory, but 
environmental (Alexander et al., 2010; 2016). Mongooses are using anal gland secretion and 
urine for communication and through this path M. mungi could spread among individuals. 
An other interesting difference of the disease appearing in mongooses is that the lesions can 
be observed in the lungs rather in advanced stage of the infection (Alexander et al., 2016). 
Other hosts than banded mongooses have not been discovered, yet (Alexander et al., 2018). 
14 
 
A close “relative” of the aforementioned MTBC member, Mycobacterium suricatte was also 
discovered in South Africa, and also has a very narrow host range, so far it was detected only 
from meerkats (Parsons et al., 2013). TB caused by M. suricatte is a highly disseminated 
disease, affecting many organs (e.g. spleen, lungs, liver), however the most characteristic 
symptom is the swelling of the sub-mandibular lymph nodes (Clarke et al., 2016). 
The “dassie bacillus” was first thought to be an attenuated strain of M. microti (Wagner et 
al., 1958), but shortly after, in 1960, it was described as an independent Mycobacterium, 
isolated from rock hyrax (Smith, 1960). Later studies proved that this bacillus is wide spread 
in South Africa (Parsons et al., 2008), and it was also reported from the Middle East, 
probably transferred via a hydrax captivated in South Africa (Cousins et al., 1994). These 
animals are living in close proximity with each other what is helping this bacillus to spread 
in the groups (Parsons et al., 2008). 
The so-called “Chimpanzee Bacillus” has been cultivated from wild chimpanzee (Coscolla 
et al., 2013). However, TB had been described in case of captive chimpanzees earlier, with 
a more limited technique those were identified as M. africanum and M. tuberculosis 
infection, also close contact with human was present (Thorel, 1980; Michel et al., 2003).  
3.5 Phylogenetic relationships within the M. tuberculosis complex 
3.5.1 Phylogeny of human-adapted MTBC members 
The human-adapted MTBC strains has been classified into eight lineages, which are 
geographically structured, based mainly on large sequence polymorphisms observed in 20 
RDs and lineage specific single nucleotid polymorphisms (SNPs) (Gagneux et al., 2006; 
Firdessa et al., 2013; Tessema et al., 2013; Ngabonziza et al., 2020). “M. canettii” has an 
ancestral place on the evolutionary tree of MTBC, and considered to be an outgroup, not 
assigned to any of the lineages (Gutierez et al., 2005; Bañuls, 2015; Brites & Gagneux, 
2017). Four of the lineages are considered to be ”ancient”, they are the following: Lineage 
1 (also known as Indo-Oceanic), Lineage 5 (also known as M. africanum West Africa 1), 
Lineage 6 (also known as M. africanum West Africa 2) and Lineage 8 (Gagneux et al., 2006; 
Ngabonziza et al., 2020, Coll et al., 2014). The most recently described Lineage 8 is 
characterized based on the genomic sequence of 2 multidrog-resistant (MDR) strains so far, 
which were isolated from the African Great Lakes region (Ngabonziza et al., 2020). This 
lineage probably diverged after “M. canettii”, but before the most recent common ancestor 
(MRCA) of the rest of the MTBC. The “modern” lineages are Lineage 2 (also known as 
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East-Asian), Lineage 3 (also known as East-African-Indian) and Lineage 4 (also known as 
Euro-American) (Gagneux et al., 2006; Coll et al., 2014; Bañuls, 2015). Strains, belonging 
to Lineage 7 are described from Ethiopia and the Horn of Africa (Firdessa et al., 2013; 
Tessema et al., 2013, Coll et al., 2014, Bañuls, 2015). In an evolutional point of view it can 
be placed between the “ancient” and “modern” lineages. The so-called M. tuberculosis sensu 
stricto consists Lineage 1-4 and L7 (Gagneux, 2018).  
It has been shown that the strain type may have an impact on the outcome of disease, vaccine 
efficiency, and development of drug resistance (Coll et al., 2014). The M. tuberculosis 
lineages can be further divided into sublineages or families, which are showing not only 
different geographical distribution, but also appear to be transmitted with different efficiency 
(Bañuls et al., 2015). There are groups, which appear globally such as the Haarlem (L4.1.2) 
and Latin American (4.3), while there are also certain groups, which can be found only in a 
couple of countries, such as Ghana (L4.1.3) Cameroon (L.4.6.2) (Stucki et al., 2016). 
3.5.2 Phylogeny of animal-adapted MTBC members 
The animal-adapted strains – based on genotyping studies and genomic deletion analyses, 
characterised by specific deletions in RD 7-10 – are forming a separate group, which can be 
further divided and this clade can be tracked back to one common ancestor (Brosch et al., 
2002; Mostowy et al., 2005; de Jong et al., 2010a; Brites et al., 2018; Parsons et al., 2019) 
(See the detailed list of genes/ORFs included in RD 7, 8, 9, 10 in: Gordon et al., 1999 
Supplementary Table 4). Parsons and colleagues (2019) are distinguishing 2 sub-lineages, 
the first occurs primarily in Europe and Asia, while the second is including the strains 
evolved in Africa. The former one is including M. pinnipedii, M. orygis, M. caprae, M. 
microti and M. bovis, while the latter one is including the “chimpanzee bacillus”, “dassie 
bacillus”, M. mungi and M. suricattae. In contrast, with the previous differentiation, Brites 
and colleagues (2018) distinguished 4 clades among the animal-adapted species, or ecotypes. 
Clade A1 is identical with the second group of the aforementioned categorisation, Clade A2 
includes M. microti and M. pinnipedii, Clade A3 includes M. orygis and Clade A4 includes 
M. bovis and M. caprae. 
Within the MTBC, a clade can be distinguished according to a common deletion of RD9 
(Rv2073c locus, oxidoreductase) (Dippenaar et al., 2015). This deletion is shared by all the 
animal-adapted MTBC members, and strains belonging to M. africanum type I (L5, L6) 
(Niemann et al., 2004; de Jong et al., 2010a; Dippenaar et al., 2015; Gagnaeux, 2018; 
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Parsons et al., 2019). Further deletions are characteristic to the animal-adapted members, 
and strains of WAF2, namely the RD7, RD8, RD10 (de Jong et al., 2010a; Dippenaar et al., 
2015; Parsons et al., 2019). Interestingly strains of WAF2 have not been reported from 
animal TB cases (Comas et al., 2013; Orgeur & Brosch, 2018). M. bovis and other animal-
adapted member were found to have smaller genome size, compared to human-adapted 
MTBC members (Cole et al., 1998; Garnier et al., 2003; Bañuls et al., 2015).  
These data support the notion of the extant human pathogen, M. tuberculosis was already a 
human pathogen bacillus, when M. africanum and later M. bovis diverged, in contrast with 
the earlier hypothesis, which suggested that human TB is a result of transmission from 
animals during the Neolithic transition (Brosch et al., 2002; Gagneux, 2012; Comas et al., 
2013; Bañuls et al., 2015). In fact, genetic data implies all animal-adapted members diverged 
from, or at least next to the L6, which is considered as an “ancient” lineage among human-
adapted MTBC members (de Jong et al., 2010a; Comas et al., 2013; Coll et al., 2014; Bañuls 
et al., 2015; Dippenaar et al., 2015; Orgeur & Brosch, 2018). 
3.5.3 The most common hypothesis regarding the origin of MTBC members 
It is hypothesised that an environmental Mycobacterium evolved into an intermediate 
bacterium, able to cause tuberculosis, what was closer to “M. canettii”. As probable link 
between NTM and tuberculous bacteria primarily M. kansasii has been suggested, along with 
M. marinum and M. ulcerans (Wang et al., 2015a; Chisolm et al., 2016; Jankute et al., 2017; 
Boritsch & Brosch, 2018). The idea of the ancestor of MTBC evolving from an 
environmental bacterium is supported not only by genetic data, but also by the examination 
of the lipid constituents of the cell wall (Jankute et al., 2017). With the changes in the cell 
wall constituents, especially those regarding to the outermost layer of the mycobacterial 
membrane, an environmental Mycobacterium with low-pathogenicity and more hydrophilic 
surface might became more hydrophobic, pathogenic, able to be transmitted by aerosol. 
Evidences are appearing about megafaunal TB in the late Pleistocene, supporting the 
hypothesis of an evolutional step involving hordes of megafauna as a link on the way to 
become an “M. canettii” related low-pathogenicity organism from an environmental 
Mycobacterium (Jankute et al., 2017; Minnikin et al., 2020).  
For summary, the extreme genetic similarity suggests that all MTBC members are sharing 
one common ancestor, which was probably a human pathogen with African origin (Brosch 
et al., 2002; Gutierez 2005; Comas et al., 2013; Orgeur and Brosch 2018; Ngabonziza et al., 
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2020). This common ancestor is hypothesised by several authors to be a “M. canettii”-like 
Mycobacterium (Supply et al., 2013; Brites & Gagneux, 2017; Supply & Brosch 2017; 
Orgeur & Brosch 2018). This idea is supported by the fact that the extant STB group is a 
link between environmental and human pathogenic mycobacteria, since it has a potential 
environmental reservoir, but shows no human-to-human transmission, however it is causing 
tuberculosis exclusively in humans although (Koeck et al., 2011).  
The common African origin of MTBC and humans, as well as genetic data (e.g. similar 
dating of major branching events) indicates co-evolution of MTBC and modern humans for 
tens of thousands of years (Gagneux, 2012; Comas et al., 2013, Loddenkemper et al., 2018).  
3.6 The mycobacterial cell wall constituents 
Although the exact cell wall (CW) structure of the Mycobacterium genus is still not known, 
its remarkable complexity is out of question (Jackson, 2014; Minnikin et al., 2015; Daffé & 
Marrakchi, 2019; Dulberger et al., 2020). The mycobacterial CW is rich in various lipids, 
some of them can be commonly found in all bacteria, but many of them are unique (Figure 
2). The lipids can add up to 40% of the dry cell mass (Jackson, 2014; Daffé & Marrakchi, 
2019; Batt et al., 2020). The outstandingly high lipid content, and sophisticated lipid 
arrangement are the two factors commonly mentioned as the reason of the high 
impermeability of mycobacterial CW (Jackson, 2014; Minnikin et al., 2015; Daffé & 
Marrakchi, 2019; Batt et al., 2020; Dulberger et al., 2020).  
In this section the main lipid families are going to be introduced and their proposed 




Figure 2: Schematic picture of CW structure in M. tuberculosis (Minnikin et al., 2015) 
Beside the conventionally occurring polar lipids in the plasma membrane (e.g. 
phosphatidylethanolamine, phosphatidylinositol), mycobacteria have a polar lipid family 
called phosphatidylinositol mannosides (PIMs), which is consisted of a phosphatidylinositol 
core decorated with mannose residues (Minnikin et al., 2015; Batt et al., 2020). PIMs are 
described as constituents of the inner most membrane layer of mycobacteria (Figure 2) 
(Minnikin et al., 2015; Daffé & Marrakachi, 2019; Batt et al., 2020; Dulberger et al., 2020). 
Further CW elements, the lipomannan (LM) and lipoarabinomannan (LAM) are lipoglycans, 
having the same manno-phosphatidylinositol anchor as PIMs do, with additional 
glycolisation and they are sharing the same synthesis path (Kaur et al., 2006; Minnikin et 
al., 2015; Batt et al., 2020). In the case of LAM arabinose branches are connecting to the 
mannose residue. LM and LAM presents several lipid anchor moieties, with they can 
contribute in the conformation of inner and outer membrane, but since LM and LAM are 
sharing the same anchoring structure with PIMs probably they are supposed to be at least 
anchored in the innermost layer of CW (Figure 2) (Minnikin et al., 2015; Daffé & 
Marrakachi, 2019; Batt et al., 2020; Dulberger et al., 2020).  
The arabinogalactan (AG) is build up from branched arabinose chains, which are linked to 
galactose units of galactan (Alderwick et al., 2015; Dulberger et al., 2020). Peptidoglycan 
(PG) is composed of peptides bonded to acetylmuramic acid and acetylglucosamin sugars. 
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AG and PG are covalently linked to each other with a spacer unit, moreover the arabinose 
domains of AG serve as anchorage for MAs (Minnikin et al., 2015; Daffé & Marrakachi, 
2019; Batt et al., 2020; Dulberger et al., 2020). The AG-PG matrix can be found 
approximately as a middle layer of mycobacterial CW (Figure 2). 
Mycolic acids (MAs) are long chain α-alkyl-β-hydroxy fatty acids (FA) (Watanabe et al., 
2001; Abrahams & Besra, 2016; Batt et al., 2020; Dulberger et al., 2020;). These 
characteristic chemical components are usually 70-90 carbon atom molecules in the genus 
Mycobacterium (Minnikin, 1982; Minnikin et al., 2015; Batt et al., 2020). Two parts of 
mycolic acid can be differentiated, a longer meromycolate chain (C42-C62) and a long 
saturated α-chain (C24-C26) (Figure 3) (Abrahams & Besra, 2016; Batt et al., 2020; 
Dulberger et al., 2020). Three MA-classes can be distinguished as the α-mycolates, the 
ketomycolates and the methoxymycolates (Figure 3) (Watanabe et al., 2001; Minnikin et al., 
2015; Abraham & Besra, 2016; Batt et al., 2020). Keto- and methoxymycolates contain 
ketone or methoxy group, and an adjacent methyl branch. The α-mycolates have a 
cyclopropane ring, always in cis-configuration, while keto- and methoxymycolates can be 
further differentiated according to their cyclopropane ring either being in cis- or trans-
configuration. These long chain lipids can be found in the outer membrane of mycobacterial 
CW and the majority of them are covalently bound to AG-PG matrix (Figure 2) (Jackson, 
2014; Minnikin et al., 2015; Daffé & Marrakachi, 2019; Batt et al., 2020; Dulberger et al., 
2020).  
 
Figure 3: The schematic structure of mycolic acids. A: α-mycolate B: Ketomycolate C: 
Methoxymycolate. 
In the CW, mycolic acids can be also found esterified, mainly to trehalose, also referred as 
“cord factor”, as trehalose dimycolate (TDM), trehalose monomycolate (TMM) in various 
proportions (Jackson, 2014; Minnikin et al., 2015; Abrahams & Besra, 2016; Daffé & 
Marrakachi, 2019; Batt et al., 2020; Dulberger et al., 2020). TMM and TDM can be localised 
to the outer membrane of mycobacterial CW (Figure 2). Other MA esters are the glucose 
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monomycolates (GMM) and monomycolic glycerols (MMG) (Jackson, 2014; Minnikin et 
al., 2015). 
The relatively large (~C90) phthiocerol dimycocerosate (PDIMs) (Figure 4) and the 
phenolphthiocerol dimycocerosate are multimethyl branched long-chain FAs (mycocerosic 
acid (MC)) esterified mainly with phthiocerol and phenolphthiocerol long-chain diols (Daffé 
& Lanéelle, 1988; Minnikin et al., 2015; Batt et al., 2020). MCs can be found only in the 
strains of M. tuberculosis, Mycobacterium bovis, Mycobacterium gastri, Mycobacterium 
haemophilum, Mycobacterium kansasii, Mycobacterium leprae, Mycobacterium marinum 
and Mycobacterium ulcerans (Redmann et al., 2009), in the outer layer of mycobacterial 
membrane. Phenolic glycolipids (PGLs) are similar to phenolphthiocerol dimycocerosate, 
but the former one is having antigenic oligosaccharides linked to the phenolic residue (Daffé 
& Lanéelle, 1988; Minnikin et al., 2002; Redman et al., 2009; Minnikin et al., 2015; Batt et 
al., 2020). 
 
Figure 4: Simplyfied structure of PDIM (Minnikin et al., 2015). 
Other free lipids are diacyl trehaloses (DAT), pentaacyl trehaloses (PAT) and sulfated 
trehalose glycolipids (SGLs), belonging to acyl trehaloses (Minnikin et al., 2015; Batt et al., 
2020; Ortalo-Magné et al., 1996). These lipids are trehalose-based glycolipids acylated with 
multimethyl branched FAs (Minnikin et al., 2015; Jankute et al., 2017; Batt et al., 2020). 
Among PATs one, containing C27 mycolipenic acid (ML) has to be highlighted as it can be 
found only in M. tuberculosis. 
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Lipooligosaccharids (LOS) are a series of highly polar lipids (Minnikin et al., 2015; Batt et 
al., 2020). LOSs are built up from a trehalose-containing saccharide core, which is acylated 
with multimethyl branched FAs on the trehalose that is also glycosylated with mono- or 
oligosaccharides. This lipid family is absent in MTB strains, however it can be found in “M. 
canettii” (Minnikin et al., 2015; Jankute et al., 2017; Batt et al., 2020) 
An other group of free lipids are the glycopeptidolipids, which can be found in non-
tuberculosis causing Mycobacterium species (Batt et al., 2020). The free lipids most 
probably can be found in the outer layer of the mycobacterial CW (Figure 2) (Jackson, 2014; 
Minnikin et al., 2015; Batt et al., 2020; Dulberger et al., 2020), but in some of the literature 
they were suggested to be constituent of the mycobacterial capsule (Daffé & Marrakachi, 
2019).  
Regarding the free lipids, PGLs are less characteristic in MTB, however, they are present 
for example in “M. canettii”, M. bovis, M. marinum and M. leprae (Minnikin et al., 2015; 
Jankute et al., 2017; Batt et al., 2020). “M. canettii” presents similar PGLs to M. kansasii, 
however in the former one the main tetraglycosyl PGL underwent on a sugar loss (Minnikin 
et al., 2015; Jankute et al., 2017). Phthiodiolone dimycocerosates can be found in M. 
kansasii, but are replaced by a full set of the PDIMs in “M. canettii”. The trehalose-based 
glycolipids can be found in the CW of “M. canettii” and MTB, but not in M. kansasii. SGLs, 
similarly to the former acyl-trehalose families, are primarily produced virulent strains of 
mycobacteria. LOSs are absent in many modern MTB strains, but are produced by “M. 
canettii” and various NTM species (Minnikin et al., 2015; Jankute et al., 2017; Batt et al., 
2020). Due to these changes, the hydrophobicity of mycobacterial CW enhanced in the 
pathogenic members of the modern MTBC (Minnikin et al., 2015; Batt et al., 2020; Jankute 
et al., 2017). 
3.7 The main steps in the pathogenesis in the establishment of tuberculosis 
M. tuberculosis needs to establish pulmonary lesions in order to spread efficiently (Orgeur 
& Brosch, 2018). MTB spreads via inhaling droplets filled with bacilli, which are projected 
in the air while coughing, sneezing or even talking (Flynn & Chan, 2001; Bañuls et al., 2015; 
Getahun et al., 2015). As the first step towards to establish an infection the bacilli have to 
get into the lungs by inhaling respiratory droplets, which are containing particles small 
enough to reach the distal alveoli (Bermudez & Sangari, 2001; Pieters, 2001; Velasco-
Velázquez, 2003; Rock et al., 2008; Ahmad, 2011; Philips & Ernst, 2012; Orme & Basaraba, 
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2014). However, the bacilli are phagocytosed by alveolar macrophages, in the attempt to 
eliminate bacilli through a range of assault methods, they are able to survive and even 
multiply intracellular. By infecting the alveolar macrophages, MTB can access the 
interstitium of the lungs, and further process with the infection (Pai et al., 2016). With the 
migration of further macrophages, lymphocytes and a wide range of other host cells to the 
site of infection the formation of granuloma can be initialised (Flynn & Chan, 2001; Ahmad, 
2010). From the host’s point of view, the granuloma separates the bacilli from the host, 
prevents they spread and also concentrates the immune response to site, on the other hand it 
can be maintained due to chronic stimulation of the immune cells and form a basis for a 
tuberculous lesion (Flynn & Chan, 2001). 
Both the human immune system and MTB evolved sophisticated strategies against each 
other (Dulberger et al., 2020). While from the side of the host CD1 family (CD1a–CD1d) 
has evolved the ability to present for example MAs, SGLs, LAM, and PIMs (Ernst et al., 
1998; Moody et al., 2000; Gilleron et al., 2004; Roy et al., 2014; Busch et al., 2016; 
Chancellor et al., 2017; Dulberger et al., 2020), MTB can avoid the recognition of the bacilli, 
and cytokine responses, also inhibit TLR-2 (Toll-like receptors) by SGLs (Blanc et al., 2017; 
Dulberger et al., 2020). A set of T cells are enabling the recognition of mycobacterial 
antigens to initiate cytokine response and the clearance of infected cells (Roy et al., 2014; 
Chancellor et al., 2017; Dulberger et al., 2020).  
MTB also using PDIM to mask some pathogen-associated molecular patterns and protects it 
against reactive nitrogen (Rousseau et al., 2004; Cambier et al., 2014; Dulberger et al., 2020). 
Among other strategies MTB achieves to recruit naïve macrophages instead of microbicidal 
andones or modifies the processing and availability of peptide antigens for MHC classes 
(Tobian et al., 2003; Cambier et al., 2014; Saini et al., 2016; Dulberger et al., 2020). TDMs 
take part in blocking the fusion of phagosomes with lysosomes, promoting granuloma 
formation and enhancing granuloma caseation (Hunter et al., 2006; Ishikawa et al., 2009; 
Dulberger et al., 2020).  
If the bacilli are not eliminated from the host after the initial infection two main scenarios 
can be drawn (Flynn & Chan, 2001; Fogel, 2014; O’Garra et al., 2013; Getahun, 2015). In 
some individuals, active disease can form in a relatively short time (1-3 years), but more 
commonly a latent infection will develop. Individuals with latent infection will not show any 
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symptoms, also will not spread the disease, however in an estimated 5-10% of latent cases 
the infection will re-activate. 
3.7.1 Pulmonary tuberculosis 
When the host-pathogen equilibrium can not be established, or it gets broken active TB 
infection is established, which appears as pulmonary TB in most of the cases (Godreuil et 
al., 2006; Rodriguez-Takeuchi et al., 2019). Initially, the granuloma goes through 
liquefaction forming cavities (Godreuil et al., 2006). In the established micro-environment 
MTB cells can grow, but macrophages can not survive. The symptoms of pulmonary TB are 
persistent cough and sputum production. In the case the disease proceeds to a more advanced 
stage sputum also can contain blood, patient loses appetite and weight, moreover fever, 
sweating over night and thoracic pain can appear. 
Development of periosteal new bone formation (PNBFs) on the visceral surface of the ribs 
can be initiated by several aetiologies, one of the main causis is – in an indirect way, via a 
secondary pleural infection – pulmonary TB (Roberts et al., 1994; Santos & Roberts, 2001, 
2006; Matos & Santos, 2006). These lesions are widely used in TB-related macroscopic 
analysis (Figure 5). 
 
Figure 5: PNBF on the visceral surface of a rib (Bélmegyer-Csömökidomb, grave no.:12). 
3.7.2 Extra-pulmonary tuberculosis 
The replication of the bacilli in macrophages and lymph nodes can lead to dissemination and 
the establishment of extra-pulmonary TB (Getahun et al., 2015). Extra-pulmonary TB was 
registered in 16% of all incident cases in 2019 (WHO, 2020). The two most commonly 
occurring forms are lymphadenitis and pleural TB (Golden & Vikram; 2005; Rodriguez-
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Takeuchi et al., 2019). As the result of the mycobacterial dissemination further extra-
pulmonary forms can develop such as, abdominal TB, miliary TB, genitourinary TB, 
osteoarticular TB, CNS TB, etc. 
The osteoarticular tuberculosis develops in a low number of TB cases, however it occurs in 
10-35% of people with extra-pulmonary TB (Golden & Vikram, 2005; Spekker et al., 2018; 
Rodriguez-Takeuchi et al., 2019). The half of skeletal tuberculosis cases are involving the 
spine (Goldan & Vikram, 2005; Spekker et al., 2018; Rodriguez-Takeuchi et al., 2019). In 
the early stage of spinal TB, the hypervascularisation of the vertebral bodies (traces of 
vertebral vasculitis) can be indicative (Baker et al., 1999; Pálfi et al., 2012; Mariotti et al., 
2015; Spekker et al., 2018, Spekker, 2018). A very distinctive manifestation, tuberculous 
spondylitis (Pott’s disease) affects mainly the thoracic region, typically involving two or 
more vertebrae, however in rare cases, solitary vertebral involvement is also recorded 
(Aufderheide & Rodríguez-Martín, 1998; Ortner, 2003; Golden & Vikram, 2005; Spekker 
et al., 2018; Rodriguez-Takeuchi et al., 2019). Due to the development of osteolytic lesions, 
wedging and eventually the collapse of vertebral bodies can be observed, leading to different 
deformities, such as to the so called “Pott’s gibbus”, which is a sharply angular kyphosis 
(Figure 6A) (Aufderheide & Rodríguez-Martín, 1998; Ortner, 2003; Spekker et al., 2018). 
Tuberculous spondylitis as well as extra-spinal TB can be accompanied by the formation of 
cold abscess around the osteolytic lesion, which can extend downwards, affecting not only 
the underlying bones but the ligaments and soft tissue, however cold abscess can be 
originated from the soft tissue, as well (Aufderheide & Rodríguez-Martín, 1998; Ortner, 
2003; Pálfi et al., 2012; Esteves, 2017; Procopie et al., 2017; Spekker, 2018). The extension 





Figure 6: A: Pott's gibbus on the thoracic region (Győrszentiván-Révhegyi tag, grave no.: S0603; B: 
Probable traces of an overlying cold abscess on the ventral surface of a sacrum 
(Sárrétudvari-Hízóföld, grave no.: 5) 
The second most common form of skeletal tuberculosis is tuberculous arthritis, typically 
affecting high-weight bearing joints, principally the knee (gonitis tuberculosa) and hip 
(coxitis tuberculosa) (Figure 7) in a monoarticular form (Golden & Vikram, 2005; Spekker, 
2018; Rodriguez-Takeuchi et al., 2019). It might begin on the synovial membrane, from 
where it continues with the erosion of the margin of the articular cartilage, and the 
destruction eventually can reach the bone (Rodriguez-Takeuchi et al., 2019). Extra-spinal 
TB osteomyelitis is a rare manifestation, mainly affecting the long and short tubular bones 
(Malaviya & Kotwal, 2003; Spekker, 2018; Rodriguez-Takeuchi et al., 2019). Pathogens 
first induce granulomatous inflammation in the cancellous bone, resulting round or oval 
shaped osteolytic lesions on the site. In half of the osteoarticular TB cases pulmonary TB 




Figure 7: Coxitis tuberculosa (Bélmegyer-Csömökidomb, grave no.: 90) 
In the traditional paleopathological practice the signs of osteoarticular TB have served as a 
good indicator of the presence of TB infection, however in later studies beside the described 
lesions, periosteal new bone formation on the long bones with a diffuse bilateral appearance 
has been also proven to be useful indicators of TB (e.g. Aufderheide & Rodríguez-Martín, 
1998; Marcsik et al., 1999, 2009; Pálfi & Marcsik, 1999; Hershkovitz et al., 2002; Maczel, 
2003; Ortner, 2003; Pálfi & Molnár, 2009; Pálfi et al., 2012; 2015; Spekker et al., 2012; 
Kajdocsi Lovász, 2015; Mariotti et al., 2015; Masson et al., 2015; Molnár et al., 2015; Paja 
et al., 2015). 
Extra-pulmonary TB can affect also the CNS (Golden & Vikram, 2005; Rock et al., 2008; 
Pálfi et al., 2012; Rodriguez-Takeuchi et al., 2019; Spekker et al., 2020a; Spekker et al., 
2020b). Although the occurrence of CNS TB is very low, it represents one of the most 
devastating form of TB and includes several manifestation forms, such as tuberculous 
meningitis, intracranial tuberculomas and spinal tuberculous arachnoiditis (Rock et al., 
2008; Spekker et al., 2020a; Spekker et al., 2020b). CNS TB can occur after haematogenous 
spread and starts with the development of small tuberculous foci in the brain, spinal cord or 
meninges (Rock et al., 2008; Spekker, 2018). Bacilli in the foci can either stay dormant or 
with the enlargement or rupture of one or more Rich foci can establish active CNS TB (Rock 
et al., 2008; Spekker et al., 2020a; Spekker et al., 2020b). The primary manifestation of CNS 
TB is tuberculous meningitis (TBM). Although it represents a very low ratio among all TB 
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infected cases, it has been found that many people identified as patients died of pulmonary 
TB also had tubercles in their CNS (Vinnard & Macgregor, 2009). The most common form 
of CNS TB is leptomeningitis (Golden & Vikram, 2005; Rock et al., 2008). Due to the 
formation of a dense gelatinous exudate the flow of cerebrospinal fluid can be distracted, 
leading to hydrocephalus (Rock et al., 2008). Tuberculomas can also develop in the brain, 
when tubercles in the brain parenchyma grow but without rupturing. 
Granular impressions (GI) (Figure 8) on the inner surface of the skull have been suggested 
to be TBM related lesions Schultz, 1993, 1999, 2001, 2003; Maczel, 2003; Spekker, 2018; 
Spekker et al., 2020a). They might be the result of pressure atrophy caused by the tubercles 
formed in the dura mater. Abnormally pronounced digital impressions (APDIs) can develop 
due to a long lasting increased endocranial pressure forming shallow depressions (Schultz, 
1993, 2001, 2003; Spekker et al., 2020b). Abnormal blood vessel impressions (ABVIs) and 
periosteal appositions (PAs) (Figure 8) on the endocranial surface can occur as a result of 
inflammatory or haemorrhagic reaction caused (Schultz, 1993, 1999, 2001, 2003; 
Hershkovitz et al., 2002; Maczel, 2003; Spekker, 2018). 
 
Figure 8: GI covered with PA on temporal bone (Szentes ̶ Borbásföld, grave no.: 9) 
However, the aforementioned GI, APDI, ABVI, PA, are not undoubtedly pathognomonic 
lesions they involvement in paleopathological investigations is necessary to draw a more 
exact paleoepidemiological picture (Schultz, 1993, 1999, 2001, 2003; Maczel, 2003; 
Hershkovitz et al., 2002; Maczel, 2003; Masson et al., 2015; Molnár et al., 2015; Schultz & 
Schmidt-Schultz, 2015; Spekker, 2018; Spekker et al., 2020a; Spekker et al., 2020b).  
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3.8 Molecular biological and analytical methods in the use of ancient TB 
detection 
As it was discussed above, paleopathology is using a broad variety of markers, which are 
observable by macroscopic investigations. However, as it was mentioned, skeletal TB and 
CNS TB develop in rare cases, moreover many markers are not pathognomic. To estimate 
the exact number of TB affected individuals in past populations is nearly impossible, 
however with the simoultaneous involvement of molecular biological and analytical 
techniques there are promising possibilities to draw a cleaner picture about the 
paleoepidemiology of TB. 
3.8.1 The development of aDNA techniques for TB diagnosis 
As the result of the mycobacterial DNA dissemination, the traits of the genomic material can 
be trapped in the mineralized tissue of the skeleton, in the dental root canal and in the pulp 
chamber (Donoghue et al., 2017). From a paleopathological point of view an advantageous 
attribution of mycobacteria is that their DNA is quite resistant to degradation due to the 
complex and protective CW, as well as the high guanidine and cytosine proportion 
(Spigelman & Donoghue, 2003; Donoghue et al., 2017). The first PCR-based detection of 
TB aDNA, extracted from morphologically TB positive ancient bone samples was published 
in 1993 (Spigelman & Lemma, 1993). The results were verified by independent laboratories 
and sequencing. Shortly after, Salo and colleagues (1994) gained similar results from an 
other Pre-Colombian specimen, using the nested PCR targeting the same 123 bp region in 
the IS6110 locus. Later commercial kits and hot-start PCR were included in the 
investigations for better specificity from complex samples (Taylor et al., 1999; Donoghue et 
al., 2017). At the end of the ‘90s spoligotyping was also introduced in TB aDNA 
investigations and further markers were included such as mtp40 and oxyR (Taylor et al., 
1999; Mays et al., 2001). In the 2000’s the method was further supplemented with other PCR 
markers such as, IS1081, outer and internal primers for TbD1, RD deletion regions (Zink et 
al., 2001; Fletcher et al., 2003; Taylor et al., 2005; Hershkovitz et al., 2008). As in 2010’s 
sequencing techniques had a breakthrough regarding sensitivity, speed as well as 
availability, whole genome sequencing, metagenomics analyses and hybridization capture 
with next generation sequencing have been also included in ancient TB research what helped 
researchers to extend the knowledge of the diversity and spread of mycobacterial pathogens 
(Bouwman et al., 2012; Chan et al., 2013; Bos et al., 2014; Kay et al., 2015).  
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3.8.2 The development of lipid biomarker based techniques for TB diagnosis 
An integrated procedure for the detection of characteristic lipid biomarkers was published 
in 1993 by David E. Minnikin and colleagues (Minnikin et al., 1993). The method included 
the detection of MAs, tuberculostearic acid (TSA) and MCs. After the lipid extraction lipids 
were purified by solid phase extraction (SPE) on normal phase (NP) cartridge. MA detection 
was carried out via HPLC-FLD (high performance liquid chromatograph connected to 
fluorescence detector) by the application of 9-anthrylmethyl ester derivatisation after reverse 
phase (RP) SPE purification. MAs were first separated according to type on NP-HLPC, then 
individual MA types have been further separated on RP-HPLC. TSA and MCs were 
derivatised with pentafluorobenzyl bromide (PFB) for GC-FID-ECD (gas chromatograph 
coupled with flame ionisation and electron capture detector) and GC-ECD, respectively. 
However, the previously described method was developed for clinical diagnosis shortly 
after, it was used for the detection of ancient TB infection with minor changes (e.g. an initial 
RP-HPLC separation was added before preceding the NP-HPLC separation) by detecting 
MAs from a 1400 years old calcified pleura sample and two approximately 1000 years old 
rib samples of morphologically TB positive cases along with aDNA analysis (Gernaey et al., 
1998; Donoghue et al., 1998; Gernaey et al., 2001). A new and more sensitive version of 
MA detection was published in 2008 by Hershovitz and colleagues (Hershovitz et al., 2008). 
The samples used for the demonstration were taken from a woman and an infant buried 
together having TB-related bone lesions. The individuals were unearthed from a 9000 years 
old, Neolithic excavation site, called Atlit-Yam. The extracted lipids were first derivatised 
with PFB, then purified on NP-SPE. Then PFB-MAs were further derivatised with 
pyrenebutyric acid (PBA) and purified on C18 RP-SPE. PBA-PFB mycolates were further 
extracted and analysed first by RP-HPLC-FLD. Components corresponding to PBA-PFB 
mycolates were collected for further analysation on NP-HPLC-FLD, where α-, methoxy- 
and ketomycolates were separated. The individual mycolate types were collected separately 
and examined on RP-HPLC-FLD, where individual mycolates were separated. In this study 
both individuals have been proven to be positive to TB by aDNA as well as mycolic acid 
examination. 
A different approach was also introduced in first half of the last decade. This method was 
also principally developed for clinical diagnosis of TB (Szewczyk et al., 2013). The method 
based on HPLC-MS/MS examination, with electrospray ionisation (ESI). The analyses 
targeted 10 of the most abundant and characteristic MAs of M. tuberculosis, multiple 
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reaction (MRM) pairs including α-, methoxy- and ketomycolates. The preparation did not 
include any derivatisation, furthermore, the samples were analysed by flow injection 
analyses, both features contributed in the establishment of a rapid procedure. The method 
was first used on archaeological samples in the next year (Borowska-Strugińska et al., 2014). 
The samples derived from a 30-50 years old male, buried in the Neolithic period, whose 
macromorphological examination described him as a TB positive individual. The previously 
described clinical method was applied, but the MS detection was supplemented with further 
MA targets, monitoring 14 MRM transition pairs. The MA profile recorded from the 
examined samples presented a similar distribution to M. tuberculosis, moreover the lipid 
biomarker based results were confirmed by PCR analysis of the extracted aDNA.  
A further optimised method was introduced for establishing mycocerosate profile and 
detecting C27 mycolipenic acid from historical bone samples, which was published in 2009 
(Redman et al., 2009). The optimisation results were tested and demonstrated on samples 
taken from individuals of the Coimbra Identified Skeletal Collection. The examined 
biomarkers were C26, C27, C29, C30, C32, C33, C34 mycocerosic acids and C27 ML. The 
extracted MC and ML containing fraction was first derivatised with PFB and further 
extracted, and then purified on NP-SPE. The collected fractions were analysed on NP-HPLC 
due to the separation of multimethyl-branched FA-PFB esters from other PFB FA esters, 
and the multimethyl-branched FA-PFB esters were collected. For the proper timing of the 
fraction collection from the HPLC, two co-markers, decafluorobenzophenone (DFBP) and 
long-chain (C6, C8, C12, C16 and C18) esters of decafluorobenzhydrol were applied, which 
are eluting after and before the targeted fraction, as follows. The collected PFB-esters were 
measured by negative ion chemical ionisation gas chromatograph coupled with mass 
spectrometer (NI-CI GC-MS) in selected ion monitoring (SIM) mode. The C26, C33, C34 
mycocerosic acids were excluded from their study as no definitive ion signals were observed. 
From the standard M. tuberculosis PN cells the C29, C30 and C32 MCs were extracted in 
the highest ratio, along with the C27 ML. Among the 49 examined bone samples 33 
mycocerosate positive samples were found. 22 out of the 33 correlated with a positive 
diagnosis for tuberculosis, and only 2 individuals who were diagnosed with pulmonary 
tuberculosis presented negative results for mycocerosates. 
31 
 
3.8.3 Examples of the combined macroscopic, aDNA and lipid biomarker based 
examinations 
A 7000-year-old male skeleton, with signs of hypertrophic pulmonary osteoarthropathy 
(HPO) from the Hódmezővásárhely-Gorzsa Neolithic site has been widely examined 
(Masson et al., 2013; Donoghue et al., 2017). HPO is a periosteal new bone formation, what 
appears symmetrical (diffuse or distal) mainly on the shaft of the long bones. Its appearance 
as a primary pathology is considered to be very rare, the secondary form is a more common 
pathological feature. The formation of HPO can be initiated by several diseases, such as 
cancer, abdominal neoplasm, liver cirrhosis, chronic intrathoracic infection (such as TB). 
The macroscopic examinations indicated that the described secondary HPO was the result 
of TB infection. Multiple samples taken from this individual were analysed for the presence 
of TB derived aDNA, MA and MC, C27 ML. Some samples were positive to the presence 
of IS1081, but not for IS6110, the MA analyses presented a weak initial RP-HPLC profile, 
in a similar distribution to M. tuberculosis standard, moreover the MC and ML examination 
provided strong evidence of the presence of MTB. Later 4 other individuals from the site 
were examined in a similar manner, as they also presented TB-related lesions based on 
macromorphological observation (Masson et al., 2015; Donoghue et al., 2017). TB infection 
was confirmed in the case of two individuals by strong MC and clear MA profiles, in the 
case of one individual by strong MC and weak MA, and in one case by strong MC, weak 
MA profile and positive aDNA analysis. 
An extensive study involving 20 individuals was published in 2015, where 6 individuals 
presented signs of skeletal TB, and other TB-related lesions were described on 13 individuals 
(Pálfi et al., 1992; Pálfi & Cernus, 1990; Molnár et al., 2015). Samples taken from 4 
individuals were positive for MA, MC, ML, infection was also confirmed by aDNA in one 
case among them, and one case indicated a M. tuberculosis - M. leprae co-infection (Molnár 
et al., 2015; Donoghue et al., 2017). Samples of 7 individuals presented clear traits of C27 
ML, but the MA and MC signals were less convincing, 5 among them was supported by 
positive aDNA results. Samples of 2 individuals presented good C27 ML, weak MC 
preservation, without observable trait of MA, one of them with positive aDNA results. In 
one case positive aDNA amplification was supported by weak C27 ML traits. Samples of 4 
individuals provided inconclusive profile for MC and C27 ML, however one of them was 
proved to be TB positive by aDNA examination. 2 individuals showed no evidence of lipid 
biomarker presence, but one of them was successfully confirmed by aDNA examination. 
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The oldest human cases verified by lipid biomarkers were unearthed in the archaeological 
site Dja’de el Mughara, Northern Syria (10.8–10.3 thousand years old, pre-domestication 
era) and Tell Aswad, Southern Syria, (10.2–9.6 thousand years old, early-domestication era) 
(Baker et al., 2015; Dongohue et al., 2017). Multiple samples of 2 individuals were tested 
for the traits of both TB related lipid biomarkers and aDNA. One of the individuals was 
tested positive for TB by aDNA examination, moreover it presented clear C32 mycocerosate 
peaks, as well as a convincing signal for C27 mycolipenate. Samples taken from the other 
individual presented strong C27 mycolipenate and weak mycocerosate signals, with no 
amplified aDNA fragments. The macromorphological analyses suggested TB infection in 
both cases. 
The oldest TB case verified by aDNA and lipid biomarker is derived from samples taken 
from the metacarpal of a Bison antiquus, dated to be 17000 years old (Pleistocene age), 
unearthed from Natural Trap Cave, Wyoming, USA (Lee et al., 2012; Donoghue et al., 
2017). The aDNA examination confirmed the presence of MTBC DNA traits, with the 
exclusion of M. bovis. MA profile was recorded, however it was weak, but the MC and ML 
profiles were strong. On the sampled metacarpal bone pronounced lesions “undermining the 
articular surface” were observed, what correlates with lesions in humans. 
The oldest evidence of TB in Argentina was verified by macroscopic technique as well as 
both lipid biomarkers and aDNA analysis (Luna et al., 2020). TB related lesions were 
observed on several vertebrae, ribs, on the ilia and appendicular skeleton. Multiple samples 
were also taken for both molecular biological and analytical examinations. One of the rib 
samples provided excellent, diagnostic MA profile on all the levels of HPLC analysis. The 
same rib sample provided strong positive profile of MCs and small indecisive signal of C27 
ML. Slightly weaker, but similar profile was also gained from an other rib sample. However, 
recovering high quality aDNA for whole genome sequencing was not achieved, positive 
result for the IS6110 insertion sequence was recorded with the analyses of the sample taken 
from the same rib, which provided the best lipid biomarker results. The given MC profile 
with the major C29 MC component indicates the presence of a slightly unusual member of 
the MTBC. MCs of M. bovis can be smaller compered to M. tuberculosis. The authors 
suggested that investigation of M. pinnipedii would be informative, as this species was 
proposed to take part in the transfer of ancient TB from marine mammals, (e.g. seals) to old 
costal Peruvians 1000 years ago (Bos et al., 2014; Luna et al., 2020). 
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When both mycobacterial aDNA and lipid biomarker analysis is carried out, it is possible to 
recover the latter one from the samples that have already undergone DNA extraction (Lee et 
al., 2012; Donoghue et al., 2017). The above described cases are excellent examples of the 
increased efficiency achieved by the combination of different approaches. 
For the verification of new methods, and the estimation of reliability of new markers in 
macroscopic analysis paleopathologists usually use well-documented collections of 
skeletons and mummies from the pre-antibiotic era (Roberts et al., 1994; Santos & Roberts, 
2001; 2006; Pálfi et al., 2012; Spekker, 2018; Spekker et al., 2020a; 2020b) The Vác mummy 
collection is one of the well-documented and broadly studied collections. Among other 
advantages of this collection, several results of TB-related investigations and individual data 
are available regarding this group (Szikossy et al., 1997; Pap et al., 1999; Fletcher et al., 
2003; Chan et al., 2013; Kay et al., 2015; Pap et al., 2017). As these mummies are dated to 
the modern age, but they are from the pre-antibiotic era, they also represent an excellent link 
between recent and archaeological samples. They were discovered during the renovation of 
the Dominical Church of Vác (1994-1995) a long-forgotten crypt (Pap et al., 1999) (Figure 
9). The chamber had been in use between 1731 and 1838 as a burial site for middle-class 
families and ecclesiastical individuals. On the site, the remains of 265 individuals were found 
and, fortunately, most of them were naturally mummified due to the special microclimatic 
features. The mummies are curated in the Department of Anthropology, Hungarian Natural 
History Museum, Budapest. Since then, the remains have undergone several investigations 
from many aspects, with a broad variety of techniques, such as morphological analysis, 
dermatological examination, X-ray imaging, 3D reconstruction, and aDNA examination 
(Szikossy et al., 1997; Pap et al., 1999, 2017; Fletcher et al., 2003; Kustár et al., 2011; Chan 
et al., 2013; Cseplák et al., 2015; Kay et al., 2015). As TB was already a growing burden all 
around Europe, including Hungary and the suspicion of TB-infected cases arose based on 
macroscopic observations, an extended screening was carried out searching for DNA traits 
of the infectious agent (Fletcher et al., 2003). 350 samples belonging to 168 individuals were 
examined by Fletcher and her colleagues. The samples were taken from the lungs, pleura, 
abdomen, ribs, hair, teeth, and clothing. In their study 55% of the individuals proved to be 
infected with Mycobacterium tuberculosis complex (MTBC), based on the PCR 
amplification of IS6110, 19-kDa antigen and MPB70 antigen genes, as well as dnaA-dnaN 
spacer regions. Moreover, they monitored the silent point mutations of the gyrA 95 and katG 
463 genes. In a later study, metagenomics analysis was also carried out on a lung tissue 
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sample taken from Terézia Hausmann, revealing the signs of a mixed infection, with the 
presence of two different M. tuberculosis strains (Chan et al., 2013). In 2015, samples of 26 
Vác mummies were studied, extracted MTBC DNA was sequenced (Kay et al., 2015). Based 
on the sequencing results phylogenetic analysis was carried out. From eight individuals, 14 
different M. tuberculosis genome sequences have been successfully determined. 
Furthermore, each infectious agent belongs to the M. tuberculosis lineage 4, which is 
represented in a high occurrence globally even today (Kay et al., 2015; Stucki et al., 2016).  
 
Figure 9: The source of the Vác mummies. A: The Dominican church of Vác. Photo: András 
Thumbasz B: The late Damiani Terézia (Body No: 79, Inv. No: 2009.19.79.) C: Sampling the Vác 





4 AIMS AND OBJECTIVES 
 
Due to the vast burden caused by TB (WHO, 2020), this disease is still in the focus of 
research. With the emergence of MDR- and XDR-TB (extensively drug-resistant TB) strains 
the better understanding of evolutionary changes of the causative agent is surpassingly 
important. For a long time, paleopathology contributed to this aim with the 
macromorphological analysis of TB infected cases among past populations (e.g. 
Aufderheide & Rodríguez-Martín, 1998; Marcsik et al., 1999, 2009; Pálfi & Marcsik, 1999; 
Ortner, 2003; Maczel, 2003; Pálfi & Molnár, 2009; Pálfi et al., 2012; Kajdocsi Lovász, 2015; 
Spekker et al., 2018; Spekker et al., 2020a; Spekker et al., 2020b). Most of the TB-related 
bony lesions are the result of extra-pulmonary TB, which was registered only in 16% of all 
incident cases in 2019 (WHO, 2020), thus to achieve a more accurate paleoepidemiological 
estimation of TB infected cases among past populations from the ‘90s molecular biological 
and analytical methods started to be involved in the paleopathological studies, adapting 
clinical protocols (e.g. Spigelman & Lemma, 1993; Salo et al., 1994; Taylor et al., 1999; 
Mays et al., 2001; Zink et al., 2001; Fletcher et al., 2003; Hershkovitz et al., 2008; Redman 
et al., 2009; Chan et al., 2013, Kay et al., 2015). The combined application of macroscopic, 
aDNA and lipid biomarker based methods resulted outstanding results (e.g. Donoghue et al., 
1998; Gernaey et al., 1998; Hershkovitz et al., 2008; Donoghue et al., 2010; Lee et al., 2012; 
Baker et al., 2015; Lee et al., 2015; Masson et al., 2015; Minnikin et al., 2015; Molnár et al., 
2015; Luna et al., 2020; Donoghue et al., 2017). As the aforementioned examples present, 
the lipid biomarker-based diagnostic methods, were proven to be efficient and reliable in 
numerous cases, hence we chose to optimise a similar method. 
The most relevant detection method of mycolic acids from human archaeological samples 
was described by Hershkovitz and colleagues in 2008. The described process consists a very 
detailed sample pre-treatment. The initial lipid extraction is followed by two further solid 
phase extraction purification steps, as well as with a complex derivatisation protocol, which 
provides great sensitivity and specificity. The analysis of the purified MAs is carried out by 
an initial RP-HPLC separation, followed by the separation of MA types on NP-HPLC. The 
separated and collected MA types are further analysed in a final RP-HPLC measurement. 
A different approach was also introduced in 2014 (Borowska-Strugińska et al., 2014). The 
method based on HPLC-MS/MS examination, with electrospray ionisation (ESI). Their 
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analyses targeted 14 of the most characteristic MAs expressed in M. tuberculosis including 
representatives of α-, methoxy- and ketomycolates. The targeted lipids were analysed in 
multiple reaction mode. As their protocol did not include any derivatisation and the samples 
were analysed by flow injection analyses, the established procedure was rapid. 
For TB diagnosis on historical bone samples based on mycocerosates and C27 mycolipenic 
acid one method has been published so far (Redman et al., 2009). The extracted MC and ML 
containing fraction was initially derivatised with PFB and further extracted, followed by a 
NP-SPE purification. The collected fractions were analysed on NP-HPLC due to the 
separation of multimethyl-branched FA-PFB esters from other FA-PFB esters. The 
multimethyl-branched FA-PFB esters were collected and measured by NI-CI GC-MS in SIM 
mode. 
Two of the above mentioned methods for the detection of MA, MC and ML C27 are used 
for a long time (Hershovitz et al., 2008; Redman et al., 2009; Lee et al., 2012; Donoghue et 
al., 2017) and proved their outstanding relevance in many cases, however they both include 
a very complex sample pre-treatment procedure. 
Our aim was to establish a lipid biomarker based HPLC-MS method, for TB diagnosis in 
historical human samples, as this instrumentation is available in many laboratories, and has 
the potential of a quick and sensitive and at the same time affordable measurement protocol. 
The main objectives of this PhD dissertation are the following: 
1. Development and optimisation of a HPLC-MS method for the detection of the two most 
commonly used lipid biomarkers, namely the mycolic acids and mycocerosic acids. 
2. Development of a lipid profile library, regarding both mycolic and mycocerosic acids, 
which can be used as reference for diagnosis. 
3. Testing the efficiency of the established lipid biomarker based method on a well-studied 





5 MATERIALS AND METHODS 
 
5.1 Materials 
5.1.1 The used bacterial and human samples  
Two reference strains from the American Type Culture Collection (ATCC), provided by BEI 
Resources (Manassas, Virginia, USA), namely the M. tuberculosis H37Rv (NR-49098) and 
M. bovis (NR-31210) and MA standard provided by David E. Minnikin were used for 
primary verification. For the method testing, five M. tuberculosis complex strains were used 
(laboratory IDs of the isolated strains MTBC-1/2015; MTBC-254/2000; MTBC-3910/2014; 
MTBC-242/2000; and MTBC-1/8508/2014), isolated from patients diagnosed with 
pulmonary tuberculosis. Also, eight different NTM species, namely M. kansasii 1959/2018, 
M. chelonae 16/2018, M. gordonae 389/2018, M. intracellulare 7802/2017, M. avium 
16229/2018, M. chimaera 619/2018, M. abscessus ssp. abscessus 180/2018, and M. 
fortuitum complex 3/2018, from various clinical specimens were included. The clinical 
samples were isolated in two laboratories, namely the Institute of Clinical Microbiology, 
University of Szeged, Szeged, Hungary and the National Korányi Institute of TB and 
Pulmonology, Budapest, Hungary, following the national recommendations (EMMI, State 
Secretariat for Healthcare, 2018) For the identification of the isolated strains commercially 
available tests were used following the instructions of the manufacturer, (MALDI-TOF mass 
spectrometry, Bruker/Hain Lifescience) and sequencing (Cepheid, Becton Dickinson) 16S 
rDNA, rpoB and hsp 65 sequence analysis). The strains were cultured on Löwenstein-Jensen 
medium (L-asparagine, monopotassium phosphate, magnesium sulfate, magnesium citrate, 
soluble potato starch, malachite green, whole eggs, glycerol and demineralized water) for 1–
3 weeks, incubating at 37 °C. In case of adequate growth and pure culture, the strains were 
inoculated into fresh media and cultured for a further 1–3 weeks at 37 °C. The inactivation 
was carried out by heating for 4 hours in physiological saline solution and stored at -20 °C, 
after freeze-drying. For the method optimisation, 20 mg of freeze-dried bacterial material 
was used. 
5.1.2 Historical samples used for testing the developed mycocerosic acid detection 
method 
For the test of the developed mycocerosic acid detection method bone and soft tissue samples 
were taken from six individuals, selected on the base of previous positive results gained by 
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aDNA examination (Table 1). The sampled adult individuals were four females and two 
males. The analysed mummy samples (both bone and soft tissue samples) derived from the 
chest region of the examined individuals. The samples were removed by sanitized tweezers 
and stored in tightly closed bags separated well from each other at room temperature. The 
ribs have been powdered, while the soft tissues were processed in the clean laboratory of the 














#68 2009.19.68. 28 400 284 
Anna 
Schneller 
#78 2009.19.78. 48 699 459 
Erzsébet 
Virágh 
#80 2009.19.80. 37 500 193 
László 
Beniczky 
#121 2009.19.121. ~38 500 482 
Gáspár 
Steitel 
#25 2009.19.25. 58 500 227 
Terézia 
Damiani 
#79 2009.19.79. 37 519 257 
Table 1: Details of the examined individual mummies 
5.1.3 Solvents, chemicals and consumables and equipments used for measurements 
For the sample pre-treatment analytical grade methanol (MeOH), toluene, hexane isomer 
mixture, ethyl acetate, petroleum ether, diethyl ether and methyl tert-butyl ether (MTBE) 
were obtained from Molar Chemicals Ltd. (Halásztelek, Hungary). For HPLC-MS 
measurements HPLC grade isopropanol (IPA), heptane, acetonitrile (ACN), chloroforme, 
acetic acid (AcOH), formic acid and ammonium formate were ordered from the VWR 
International Ltd. (Debrecen, Hungary). The KOH, HCl solution, and consumables 
including polytetrafluoroethylene (PTFE) capped glass tubes, PTFE capped vials, glass test 
tubes, and PTFE syringe filters (pore size: 2.0 µm; diameter: 13 mm) were purchased also 
from VWR International Ltd. (Debrecen, Hungary). For the SPE purification Strata 18-E (55 
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µm, 70 A) cartridge was used (Phenomenex, Torrance, California, USA). The TLC Silica 
gel 60 plates were purchased from Merck Millipore (Burlington, Massachusetts, USA). 
During the sample preparation Christ Alpha 1-4 freeze-dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, Harz, Germany) and Savant SC250EXP SpeedVac 
concentrator (Thermo Scientific, Waltham, Massachusetts, USA) were used for freeze-
drying and solvent evaporation, respectively. Measurements were carried out on a Shimadzu 
LC-10AD VP HPLC coupled with a Shimadzu LCMS-2010A Single Quadrupole mass 
spectrometer (MS) and on a Dionex Ultimate 3000 UHPLC system (Thermo Scientific, 
Waltham, Massachusetts, USA), which was coupled with a Q-Exactive Plus MS (Thermo 
Scientific, Waltham, Massachusetts, USA). 
For the separation, a Gemini – NX C18 (3 μm, 110A, 50 mm x 2 mm) column (Phenomenex, 
Torrance, California, USA) was used. 
5.2 Methods 
5.2.1 Optimisation of the mycolic acid detection method 
5.2.1.1 Mycolic acid detection by single quadrupole LCMS 
The lipid extraction and purification was carried out following the previously published 
method by Hershkovitz and colleagues (2008) with the exclusion of derivatisation and 
simplification of the SPE purification, using the MTBC-1/2015 strain and MA standard. 20 
mg of bacterial samples were heated at 100 °C overnight with 30% KOH in MeOH (2 ml; 
m/V) and toluene (1 ml) in PTFE capped glass tubes. The tubes were cooled and 10% HCl 
(1 ml) was added in an ice bath; the pH was finally set to 1 with the addition of 37% HCl 
solution. Thereafter, toluene was added (1 ml) to the samples and after 1 min of vortexing, 
they were centrifuged at 1200 rpm for 15 min. The upper organic layer was transferred into 
a new glass tube, while the bottom layer was re-extracted twice with the same method with 
the further addition of toluene. The collected and combined organic layer was washed with 
water (1 ml). The collected and combined organic phases were evaporated to dryness in 
vacuum. The samples dissolved in minimal diethyl ether (~0.25ml) and loaded on 
500mg/3ml C18 cartridges. 
Additional 0.1 ml diethyl ether was used for rinsing the tubes. Details of the fractionation 











1 1.6 4.4  
2 0.5 5.5  
3 0.5 5.5  
4  5.5 0.5 
5  5.2 0.8 
6  2 4 
Table 2: RP-SPE purification sequence 
Collected fractions were dried in vacuum, and dissolved in diethyl ether for thin layer 
chromatography (TLC) (petroleum ether (bp 60-80°C)/ethyl acetate (80:20)) analysis. For 
revealing lipids, 5% ethanolic molybdophosphoric acid (MPA) stain was used, followed by 
drying with heat gun. RF values were compared to the ones gained from MA standard. 
The fraction containing MAs was evaporated to dryness in vacuum and dissolved in 1 ml 
chloroform for analysis carried out on Shimadzu LCMS-2010A. For the optimisation of the 
HPLC and MS settings 5µl samples were applied in flow injection analysis (FIA), with 200 
µl/min flow rate. The tested eluent compositions are shown in Table 3. Eluent A and eluent 
B were mixed in equal ratios. The initial settings of MS were the following: negative ion 
mode, the ionisation was electrospray ionisation (ESI), the targeted masses were monitored 
in scan mode, the nebuliser gas was air, curved desolvation line (CDL) and interface voltage 
were set to -40 kV and 3.5 kV respectively. The tested eluent compositions are shown in 
Table 3. 
Eluent A Eluent B  
MeOH:ACN:CHCl3 (2:4:4) 





+ 5mM NH4COOH 
IPA:MeOH:ACN (50:20:30) 
+ 5mM NH4COOH 
2 
MeOH:ACN (8:2) 
+ 5mM NH4COOH 




+ 5mM NH4COOH 
IPA:MeOH:CHCl3 (50:49:1) 
+ 5mM NH4COOH 
4 
MeOH:ACN (8:2) 
+ 5mM NH4COOH 
IPA:MeOH:CHCl3 (50:45:5) 
+ 5mM NH4COOH 
5 
Table 3: Eluent compositions tested on single quadrupole HPLC-MS 
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For the preliminary measurements 2 representatives of each MA types were chosen as target 
molecules. Details of the targeted mycolic acids are shown in Table 4. 
m/z Elemental composition Abbreviation 
1164.2 α-C80H156O3 α-C80 
1192.2 α-C82H160O3 α-C82 
1252.3 m-C85H168O4 m-C85 
1264.3 k-C86H168O4 k-C86 
1278.3 k-C87H170O4 k-C87 
1280.3 m-C87H172O4 m-C87 
Table 4: Details of the targeted mycolic acids for single quadrupole measurements 
During the optimisation of the MS settings air and nitrogen as nebuliser gasses, different 
interface and CDL voltages were tested. The efficiency of selected ion monitoring a scan 
mode was compared, as well.  
5.2.1.2 Mycolic acid detection by Q-Exactive Plus Orbitrap MS 
After the preliminary measurements the mycolic acid detection was transferred to a more 
sensitive equipment, namely to a Dionex Ultimate 3000 UHPLC coupled with a Q-Exactive 
Plus mass spectrometer. The initial eluent composition consisted MeOH:ACN (80:20) as 
eluent A, which was supplemented with 5mM ammonium-formate, and IPA:MeOH:CHCl3 
(50:45:5) supplemented with 5mM ammonium-formate as eluent B. For the measurements 
FIA was applied, and the elution was carried out with 50% eluent B on 200 µl/min flow rate. 
Samples were dissolved in 1 ml chloroform and 5µl was injected for analysis. For ionisation 









m/z Elemental composition Abbreviation 
1136.16568 α-C78H152O3 α-C78 
1164.19677 α-C80H156O3 α-C80 
1192.22797 α-C82H160O3 α-C82 
1220.26089 α-C84H164O3 α-C84 
1236.25709 k-C84H164O4 k-C84 
1252.28423 m-C85H168O4 m-C85 
1264.28755 k-C86H168O4 k-C86 
1278.30288 k-C87H170O4 k-C87 
1280.31409 m-C87H172O4 m-C87 
1292.31731 k-C88H172O4 k-C88 
1294.33209 m-C88H174O4 m-C88 
1308.26432 m-C89H176O4 m-C89 
Table 5: Details of the targeted mycolic acids for Orbitrap measurements 
The detection was carried out in scan mode. The maximum mass deviation of the targeted 
[M-H]- ions was 5 ppm for peak identification. Details of the targeted MAs are in Table 5, 
which were chosen on the base of a previously published HPLC-MS/MS method (Borowska-
Strugińska et al., 2014). For further verification of the observed peaks ions were fragmented 
in parallel reaction monitoring (PRM) with the application of collision energy of 70kV. 
Further variations of eluent compositions were tested including the fine tuning of the 
chloroform concentration (from 0% to 40%), along with examination of the effect of AcOH 








Eluent A Eluent B (1-4)  
MeOH:ACN (8:2) 
+ 5mM NH4COOH 
MeOH:ACN:CHCl3 (2:4:4) 
+ 5mM NH4COOH 
1 
IPA:MeOH:CHCl3 




+ 5mM NH4COOH 
3 
IPA:MeOH:CHCl3 (50:49:1) 
+ 5mM NH4COOH 
4 
Table 6: Eluent compositions for the optimisation of CHCl3 concentration 
In the case of MS settings, spray and S-lens voltage, capillary and auxiliary gas temperature 
were optimised, while the sheath gas flow and the auxiliary gas rates were constant at 15 
l/min and 10 l/min, respectively. The detection was carried out in scan mode. 
After optimising a basic detection method for mycolic acids the pre-treatment process was 
further simplified by the exclusion of SPE purification, and the extraction protocol was 
optimised. First the efficiency of the application of 10% (m/V), 20% (m/V), 30% (m/V) 
KOH was tested along with the comparison of toluene and hexane isomer mixture as 
extraction solvent. Afterwards, with the best KOH concentration further extraction solvents 
were taken under investigation with the following compositions: extraction 3 times with 
petroleum ether (60-80 °C bp), followed by pooling the extracted organic layers; extraction 
3 times with toluene and 1 time with hexane isomer mixture, followed by pooling the 
extracted organic layers; extraction 3 times with toluene and 1 time with petroleum ether 
(60-80 °C bp), followed by pooling the extracted organic layers; and extraction 1 time with 
MTBE, 1 time with hexane isomer mixture and 1 time with petroleum ether (60-80 °C bp), 
followed by pooling the extracted organic layers.  
With the final method the bacterial MA profiles were established. For the profiling additional 
MAs were involved, which are included in the 5. Table. The area values of the monitored 
MAs were summarised in the case of each bacterial samples and then given in percent form. 
5.2.2 Mycocerosic acid separation and detection by Q-Exactive Plus Orbitrap MS 
The samples were heated at 100 °C overnight with 20% KOH in MeOH (2 ml; m/V) and 
toluene (1 ml) in PTFE capped glass tubes; for bacterial samples, 20 mg was used. The tubes 
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were cooled and 10% HCl (1 ml) was added in an ice bath; the pH was finally set to 1 with 
the addition of 37% HCl solution. Thereafter, toluene was added (1 ml) to the samples and 
after 1 min of vortexing, they were centrifuged at 1200 rpm for 15 min. The organic layer 
was transferred into a new glass tube, while the bottom layer was re-extracted twice with the 
same method with the further addition of toluene and one more time with hexane (1 ml). The 
collected and combined organic phases were evaporated to dryness in vacuum, and dissolved 
in 1000 µl and 200 µl isopropanol (IPA):heptane:ACN (4:1:5) in the case of bacterial and 
mummy samples, respectively. The sample solutions were filtered by PTFE syringe filters 
(pore size: 2.0 µm; diameter: 13 mm). 
The measurements were carried out on a Dionex Ultimate 3000 UHPLC system (Thermo 
Scientific, Waltham, Massachusetts, USA), which was coupled with a Q-Exactive Plus 
(Thermo Scientific, Waltham, Massachusetts, USA) mass spectrometer (MS). For the 
separation of the used crude extract, a Gemini – NX C18 (3 μm, 110A, 50 mm x 2 mm) 
column (Phenomenex, Torrance, California, USA) was used at 30 °C. The eluent A was 
ACN, containing 0.1% AcOH, while eluent B consisted of IPA:heptane (8:2), also 
supplemented with 0.1% AcOH. The flow rate was 200 µl/min and the applied gradient 
elution was the following: at 0 min 10% B, 5 min 15% B, 15 min 70% B, 16 min 90% B, 18 
min 90% B, 18.5 min 20% B, 19.5 min 20% B, 20 min 90% B, 23 min 90% B, 24 min 10% 
B and 28 min 10% B. The injection volume was 10 μl. The injection needle was thoroughly 
washed, before and after injection, with 150 μl IPA:heptane (8:2). Solvent blank injections 
were made between each sample investigation. The MCs were monitored in negative 
Selected Ion Monitoring (SIM) mode. Details of the targeted MCs are shown in Table 7, 
their chemical structures are shown on Figure 10.  
m/z Elemental composition Abbreviation 
409.40510 C27H53O2 C27 
437.43640 C29H57O2 C29 
451.45205 C30H59O2 C30 
479.48335 C32H63O2 C32 
493.49900 C33H65O2 C33 




Figure 10: Chemical structure of the monitored mycocerosic acids 
Initially the APCI and ESI ion sources were compared, along with the optimisation of the S-
lens voltage, the capillary and the auxiliary gas/vaporiser temperature. The sheath gas flow 
and the auxiliary gas rates were constant at 35 l/min and 10 l/min, respectively. 
The area values of the MC peaks were calculated with TraceFinder 4.0 General Quan 
Software (Thermo Scientific, Waltham, Massachusetts, USA). The maximum mass 
deviation from the calculated [M-H]- ion mass was 5 ppm for peak identification. For 
establishing MC profiles and for the evaluation of the analysed mummy samples, the 












6 RESULT AND DISCUSSIONS 
 
6.1 Optimisation of the mycolic acid detection method 
The mass spectrometric detection of MAs can be carried out with several approaches, using 
matrix-assisted laser desorption/ionization-time of flight MS (MALDI-TOFMS), MALDI 
spiral-TOFMS, HPLC-ESI-QTOF MS, HPLC triple quadrupole MS/MS, HPLC- triple 
quadrupole/ion trap MS, HPLC-ESI/APCI-TOF MS (Laval et al., 2001; Song et al., 2009; 
Bhamidi et al., 2011; Shui et al., 2011; Szewczyk et al., 2013; Teramoto et al., 2015; Yoshino 
et al., 2019). However, the method optimisation started on a Shimadzu LCMS-2010A 
system, in the second half of the method development our laboratory improved its available 
facilities and we had the chance to continue our work on a HPLC-Orbitrap MS. 
6.1.1 Mycolic acid detection by single quadrupole LCMS 
Initially, the effect of five different eluent compositions was tested on the Shimadzu LCMS-
2010A system with the application of FIA (Table 3). The main difference of the eluents was 
the CHCl3 concentration, with the first containing the highest amount (40%) and the second 
not containing any. The 3rd, 4th and 5th tested eluent contained 10%, 0.5% and 2.5% CHCl3, 
respectively. For the analysis MA standard provided by David E. Minnikin was used. With 
the first solvent mixture most of the monitored MAs with the expected [M-H]- values were 
already observed, with the exception of the k-C86 MA (Figure 11.1). The application of the 
second eluent variation resulted the appearance of the same peaks, however their calculated 
area value was at least ten times smaller, compared to the previous results (Figure 11.2). The 
third eluent composition provided the best intensity and all the monitored MAs were 
observed, although even in this case the gained intensity growth was ranging between 10% 
and 30%, depending on the targeted MA (Figure 11.3). The fourth and fifth variations 
resulted similar area values compared to the first one, but all the monitored MAs were 
detected (Figure 11.4;5). Although the highest intensity was provided by the third mixture, 
for further analysis the fifth one was chosen, as its efficiency was only slightly behind, but 
with a 7.5% lower chloroform concentration (Figure 11). The application of non-polar 
solvents is widespread in HPLC-MS based MA detection methods, which is most commonly 
chloroform, but some methods are including hexane due to its even lower polarity (Bhamidi 
et al., 2011; Shui et al., 2011; Szewczyk et al., 2013; Borowska-Strugińska et al., 2014; 





Figure 11: Comparison of the effect of 5 different eluent composition on the detection of MAs 
A specific feature of the Shimadzu LCMS-2010A system is, that it provides the option of 
the application different nebuliser gasses, hence the next step was to test whether air or 
nitrogen is the more suitable nebuliser gas for the ionisation of MAs. As it can be seen on 
Figure 12, application of air provided better results, the area values were at least 6 times 
larger. 
 
Figure 12: Comparison of the effect of nitrogen and air as nebuliser gas on the detection of MAs 
The CDL voltage was also fine-tuned, values from 0 to -100 V have been tested. The 
decrease of this value resulted only slight difference in every cases (Figure 13). The default 
setting (-25 V) provided the highest area values in the case of the monitored α-MAs, although 
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the ionisation of keto- and metoxymycolates were more efficient at -40 V, as a 10% increase 
was achieved. Keto- and metoxymycolates are least abundant in M. tuberculosis, compared 
to α-MAs (Takayama et al., 2005), hence the -40 V CDL voltage has been chosen for further 
application. 
 
Figure 13: Optimisation of CDL voltage for the detection of MAs 
The effect of changed interface voltage was also tested, starting from the basic tune setting, 
3.5 kV. The interface voltage was increased up to 5 kV with 0.5 kV steps. A slight, 20-30% 
increase was observed in the case of all monitored MAs at 4 kV and 4.5 kV (Figure 14). 
With the application of 5 kV the area values were similar to the initially measured ones. For 




Figure 14: Optimisation of interface voltage for the detection of MAs 
SIM and scan detection modes were also compared. Interestingly, detection in scan mode 
seemed scarcely more efficient (Figure 15). 
 
Figure 15: Comparison of Scan and SIM mode for MA detection 
6.1.2 Mycolic acid detection by Q-Exactive Plus Orbitrap MS 
6.1.2.1 Optimisation of a basic detection method and the identitfication of the targeted 
peaks 
The optimisation of the MA detection method on a new, more sensitive equipment has been 
started by setting a basic detection method. Beside the great sensitivity provided by this 
equipment, other advantageous features of the Orbitrap MS are, that it enables MS/MS 
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analysis, and the collected data are more prompt due to its high resolution. Initially, the 
eluents composition, optimised in the preliminary measurements (50% eluent A: 
MeOH:ACN (8:2) + 5mM NH4COOH; 50% eluent B: IPA:MeOH:CHCl3 (50:45:5) + 5mM 
NH4COOH) was used. The basic setting of the capillary voltage was 3 kV, which was first 
increased to 3.2 kV, resulting approximately 3 times higher area values in the case of the 
monitored MAs (Figure 16 MA01-MA02). As setting the capillary voltage up to 4 kV 
implied only a slight increase in the area values, further changes were not applied (Figure 16 
MA02-MA03). The temperature of the capillary was increased to 350 °C, from 300 °C, 
resulting almost 1.5 times higher area values of the targeted lipids (Figure 16 MA03-MA04). 
Increasing the S-lens voltage from 50V to 70V provided a similar result (Figure 16 MA04-
MA05), however further increase to 90V resulted only a 10% raise of the area values. Due 
to the applied optimisation steps the intensity of C78-C86 MAs become 9-10 times higher, 
while the intensity of C87-C89 MAs increased with 300%. The application of different 
nebuliser gas was not possible in the case of this equipment, as it was designed to operate 
only with high purity (99%) nitrogen gas. 
 
Figure 16: Optimisation of MS setting for a basic MA detection method 
The identities of the targeted peaks were verified with two different methods. Beside finding 
the selected targeted peaks (Table 5), further MAs have been detected in the cases of all the 
three MA classes (Figure 17), and both the targeted and not targeted MAs presented 28 
Dalton differences (two-carbon unit), characteristic to the homologous series of MAs, due 
to their biosynthesis pathway (Figure 17) (Takayama et al., 2005). The same MAs have been 
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also analysed by other mass spectrometric investigations published carried out via triple 
quadrupole analysator (Szewczyk et al., 2013; Borowska-Strugińska et al., 2014; Song et al., 
2009) and MALDI-TOF analysis (Teramoto et al., 2015; Yoshino et al., 2019), however in 
the latter case MAs were observed as Na+ adducts due to the laser mediated ionisation. 
 
Figure 17: Examples of homolgous α-, methoxy- and keto-MA series 
PRM measurements were also carried out on the MA standard provided by David E. 
Minnikin. The two most characteristic fragments were the 365.35767 and the 395.38901, 
identified as the C24 and C26 α-alkyl chain, respectively (Figure 18). The overall 
representation of 395.38901 fragment was approximately 7 times higher compared to 
365.35767 in our measurements. These fragments have been observed by other authors, as 
well, with the application of triple quadrupole MS (Szewczyk et al., 2013; Song et al., 2009), 
qTOF MS (Bhamidi et al., 2011) and CID-MS (Lehmann et al., 2018). Szewczyk and 
colleagues (2013) included two MAs in their analysis which was represented among the 
MRM pairs with both containing C26 and C24 α-alkyl chains, namely the α-C78 and m-
C85. The intensity of the 395.38901 fragment was 5 times higher in both cases. The results 
of Song and colleagues (2009), Bhamidi and colleagues (2011) and Lehmann and colleagues 
(2018) also suggested a much higher contribution of MAs with C26 α-alkyl chains among 
the analysed MTBC specimens. Fragments with 377.37360 and the 349.34717 m/z value 
were also detected, which were interpreted previously by Szewczyk and colleagues (2013) 
as the result of H2O loss of the C24 and C26 α-alkyl chains, respectively. One additional 
fragment should be also notified, detected at m/z 381.37360, which was also included in the 
proposed fragmentation pattern of the previously referred authors, suggested to be a 
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preserved fragment after the loss of the carboxyl-group and the meromycolic chain, C24 and 
C26 α-alkyl chain, respectively (Figure 18). The fragmentation was carried out with the 
application of 80 V collision energy, however according to the literature a broad range of 
voltage can be applied. Song and colleagues (2009) applied 55 eV to initiate collision 
induced dissociation. Bhamidi and colleagues (2011) used two approaches for MA detection, 
in the case of HPLC-ESI/APCI-TOF MS measurements, 120 V fragmentor voltage was 
applied, while for the analysis of the α-alkyl chains MS/MS measurements were carried out 
on a qTOF detector with the application of 75 eV for the fragmentation. For the description 
of a very detailed fragmentation pattern Szewczyk and colleagues (2013) applied unique 
collision energy for each targeted MA ranging from 74 to 88 eV.  
 
Figure 18: Schematic MA fragmentation pattern (α-C80 drawn as example) 
After verifying the observed peaks, MAs extracted from clinical samples (M. tuberculosis 
1/2015) was used for the further measurements, due to the difficulty of obtaining commercial 
MA standard. 
6.1.2.2 Optimisation of chloroform concentration of the eluent composition and MS 
settings 
The ratio of chloroform in the eluent was also fine-tuned on our HESI ion source. Nine eluent 
variations were tested, within the chloroform ratio ranging from 0 to 40% (Table 6). The 
eluent compositions (50% eluent B-3) presenting 2.5% of higher CHCl3 ratio provided 
relatively low area values (Figure 19). The lowest area values were recorded in the presence 
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of 5% chloroform (100% eluent B-3). Increasing the CHCl3 ratio in the eluent resulted 
increased area values in the case of 10% (50% eluent B-2), 20% (100% eluent B-2), 30% 
(75% eluent B-1). These eluent compositions initiated rather similar results. The efficiency 
of the eluent containing 40% of CHCl3 (100% eluent B-1) can be placed between the 
aforementioned eluent compositions, it resulted the second lowest area values of all the 
targeted MAs. Similar results were achieved with the application of 2.5% CHCl3 (100% 
eluent B-3). Eluent compositions containing 1% CHCl3 (100% eluent B-4) and 0.5% CHCl3 
(50% eluent B-4) provided similar and efficient eluent for MA detection, however the 
highest area values were gained with the eluent composition lacking CHCl3 (0% eluent B). 
 
Figure 19: Optimisation of the CHCl3 content of the eluent composition 
In a previous study the formation of chloride adducts [M+Cl]- was described due to the 
presence of CHCl3 (Song et al., 2009), hence the acquired data was analysed from a second 
aspect, seeking for the possible chloride adducts. Peaks with the calculated [M+Cl]- values 




Figure 20: Examples of the observed chloride adducts 
The formation of chloride adducts was observed in the case of the application of all eluent 
compositions. The highest values were detected in the case of the eluents containing 30% 
and 40% CHCl3 (Figure 21). The proportion of chloride adducts followed the decreasing 
CHCl3 ratio between the range of 40%-5% of CHCl3 concentration. With the further decrease 
of this highly apolar solvent the presence of the chloride adducts presented an increasing 
tendency. The eluent containing 1% CHCl3 provided similar results to those containing 30% 
and 40% of CHCl3. The further decrease of the CHCl3 was followed by decreasing area 
values of the chloride adduct. Chloride adducts were detected even with application of 
chloroform-free eluent composition due to the dissolution of samples in CHCl3. However, 
forming chloride anions purposely in negative-ion ESI-MS analyses, with the application of 
eluents containing CHCl3 has been reported as a tool for enhancing the detection of 
compounds, which are lacking highly acidic site – thus would be less efficient to detect in 





Figure 21: The effect of the CHCl3 concentration on the development of chloride adduct 
6.1.2.3 Optimisation of MS parameters along with the application of a chloroform-free 
solvent 
Due to the highly increased area values gained by the application of chloroform-free eluent 
composition, the application of MeOH:ACN (8:2) + 5mM NH4COOH was chosen for the 
further investigations in the case of QExactive instrument. With the application of the new 
solvent mixture the MS parameters were tuned again. Initially, the spray voltage was set. 
Firstly, its value was increased to 4.5 kV and then to 5 kV, each step resulting increased area 
values (Figure 22 MA06-MA07-MA08). The increase from 4kV to 5 kV results 1.3 times 
higher area values. This result is supported by other published methods, as Song and 
colleagues (2009) has applied similarly high (4.9 kV) capillary voltage. Although the 
instrumentation of the method published by Szewczyk and colleagues (2013) is not entirely 
parallel of our used equipment, in their described method 4.5 kV was applied as ionspray 
voltage. As our optimisation continued, setting the capillary voltage up to 6 kV and 7 kV did 
not initiate further increase in the area values of the targeted MAs (Figure 22 MA08-MA09-
MA10). Although the application of 5 kV as capillary voltage was more efficient compared 
to 4kV, in later measurements the instability of this value was observed, hence the capillary 
voltage was decreased to 4kV. In the next step the capillary temperature was increased to 
400 °C from 350 °C, which resulted 1.2 times increase in the measured area values. Last, 
the temperature of auxiliary gas heater was optimised. Increasing this value from 300 °C to 
400 °C resulted further 1.3 times increase in the area values. Further increase of the auxiliary 
gas heater temperature up to 450 °C resulted a minimal decrease in the area values. The 
temperatures providing the best results were close to maximum values, which can be applied 
on the equipment. The overall intensity increase, gained by the introduced optimisation 
56 
 
steps, was up to 230%. The application of particularly high temperature was also described 
in the ESI-MS/MS method developed by Szewczyk and colleagues (2013), within the 
ionspray temperature was set to 650 °C, however the method described by Bhamidi and 
colleagues (2011) involved the drying gas and vaporiser temperature set to 300 °C and 200 
°C, respectively on a TOF mass spectrometer supplemented with an APCI/ESI multimode 
source. 
 
Figure 22: Optimisation of MS setting with the application of MeCN:MeOH (8:2) + 5mM ammonium 
formate eluent 
6.1.2.4 Optimisation of the sample pre-treatment protocol 
Beside the optimisation of the detection method of the selected lipids their extraction 
protocol was also fine-tuned. Initially three different KOH concentration were compared 
with the involvement of 2 representatives of each MA types. In the original published 
method 30% (m/V) KOH, dissolved in MeOH, was applied for saponification, followed by 
extraction with toluene (Hershkovitz et al., 2008). All the targeted MAs were providing 
detectable peaks (Figure 23). The application of 20% KOH did not affect the amount of the 
extracted MAs. Further decrease of the KOH ratio in the solution down to 10% negatively 
affected the efficiency of the saponification regarding MAs. During this sample preparation 
round the effect of two extraction solvents, toluene and hexane was also compared. The 
application of hexane isomer mixture for extraction, after saponification with 30% KOH, 
resulted 1.3 times higher outcome regarding the involved α-MA specimens and a slighter, 
approximately 20% increase in the case of methoxy-MA, while negatively affected the 
efficiency of the extraction of keto-MAs. The application of hexane isomer mixture beside 
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10% KOH concentration provided similar result to those gained with the application of 
toluene.  
 
Figure 23: Comparison of different KOH concentrations and the appliaction of toluene and hexane as 
extraction solvents 
The previously introduced results suggested that the application of hexane has a good effect 
on the extraction of α- and methoxy-MAs, but for the extraction of keto-MAs the application 
of toluene is necessary, hence in this comparison the originally used extraction 3 times with 
toluene (T) was supplemented with one additional hexane isomer mixture extraction (H), 
followed by the pooling of the extracted organic layers (Figure 24). This extraction scheme 
was tested in an other composition within the extraction with toluene was supplemented with 
one additional petroleum ether (PE) (60-80 °C) extraction. Furthermore, the application of a 
3 times petroleum ether (PE) (60-80 °C); and the application of one time methyl tert-butyl 
ether (MTBE), one time hexane, and one time PE extraction protocolts were tested. 
Regarding the α- and methoxy-MAs the application of the toluene-hexane extraction 
provided the best results. The extraction carried out with PE resulted the second best 
efficiency of α-MA extraction. The highest keto-MA content was measured from samples 
extracted with only PE, however the amount of methoxy-MAs decreased compared to the 
previously described results. The extraction carried out with toluene supplemented with PE 
provided the second best results regarding the methoxy-MAs, although the efficiency of the 
α- and keto-MA extraction was behind the efficiency of the previous two extraction solvents. 
The lowest extraction outcome regarding all MAs was achieved with the application of the 
solvent mixture consisting MTBE, hexane and PE. For further application 20% KOH 
58 
 
solution and toluene supplemented with hexane isomer mixture has been chosen for sample 
pre-treatment. 
 
Figure 24: Comparison of the effect of 4 extraction solvent compositions 
Very diverse sample pre-treatment protocols are described in studies covering MA detection 
methods from sputum and bacterial samples, whose diversity originated from the number of 
detection techniques applied for the MA measurements. However, in these methods there 
are some commonly used steps, such as the saponification and the acidification before the 
extraction into the non-polar organic solvent. In the method applied by Yoshino and 
colleagues (2018) the pre-treatment started with saponification of the bacterial cell material 
with the application of 5 N NaOH. Samples were heated for 20 min at 121 °C. The cooled 
samples were acidified prior to the extraction with n-hexane. The collected organic phase 
was first washed with water. After discarding the water, CHCl3 was added to samples. It was 
followed by double overnight precipitation of MAs with the addition of MeOH. From the 
purified crude MA fraction MA methyl esters (MA-ME) were prepared with the application 
of 10% tri-methylsilyldiazomethane in n-hexane. MA-MEs were checked by TLC. After 
recovering the purified MA-ME fraction with the application of CHCl3:MeOH (9:1) the 
samples were autoclaved with the addition of toluene, MeOH and NaOH. Samples were 
acidified and further extracted with n-hexane. 
Bhamidi and colleagues (2011) described a complex experimental study regarding the cell 
wall core structure of M. tuberculosis and M. leprae. As many CW components were 
involved in their investigation, the purification of MAs was carried out with a complex 
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protocol. Initially the mAGP matrix was extracted mechanically in PBS buffer. The gained 
pellet was suspended overnight in 2% SDS dissolved in water. After the removal of the 
supernatant the pellet was heated at 100 °C in SDS solution for an hour. The resulted pellet 
was suspended in 80% acetone. After the removal of SDS samples were washed in water 
and treated with CHCl3:MeOH (2:1) to remove the free MAs. The extracted mAGP was 
treated with TFA for 2 h at 121 °C and extracted with CHCl3. MAs were de-esterified from 
the AGP matrix by alkaline hydrolysis, followed by acidification. The acidified samples 
were extracted with diethyl ether.  
In contrast with the above described protocols in many studies less complex methods were 
used for pre-treament, which are more similar to the one used in our study. Teramoto and 
colleagues (2015) initiated their sample treatment with saponification in 10% KOH 
dissolved in MeOH, for 2 hours, while the samples were heated at 90 °C. MAs were extracted 
with hexane, prior to MA-ME development with diazomethane. The initiate alkaline 
hydrolysis in the study of Song and colleagues (2009) was carried out with the application 
of 25% KOH in MeOH:H2O (1:1) for an hour at 90 °C, followed by the addition of CHCl3 
and HCl. The removed organic layer was used for further MA analysis. Similar approach 
was applied by Szewczyk and colleagues (2013), however, they pre-washed the cells in 
MeOH, the KOH was dissolved in MeOH, and the extraction with CHCl3 was carried out in 
a separate step. Pre-treatment before saponification was applied by Sui and colleagues 
(2012), as well. For the inactivation of the pathogens and the removal of free-lipids samples 
were shaken overnight in CHCl3:MeOH (2:1) at 4 °C. After separating the layer with the 
addition of H2O organic solvents were removed, and the pre-treatment was repeated, while 
pooling the collected organic layers. The appearing intermediate layers were collected, dried 
and treated with 20% tetrabutylammonium hydroxide. Samples were heated at 105 °C for 2 
hours. The cooled samples were acidified and extracted with hexane. Relatively high, 40% 
KOH concentration was applied by Laval and colleagues (2001). Bacterial cells were heated 
for 3 hours at 100 °C in the aqueous KOH solution and methoxy ethanol. After acidification 
MAs were extracted with diethyl ether. MA-ME were prepared with diazomethane solution. 
6.1.2.5 Mycolic acid profile establishment of MTBC and NTM strains 
After optimising the sample pre-treatment and detection method, development of 
mycobacterial MA profile library has been started. As a “test library” the MA profiles of 
MTBC-1/2015; MTBC-254/2000; MTBC-3910/2014; MTBC-242/2000; and MTBC-
1/8508/2014 (Figure 25), Mycobacterium gordonae 389/2018, Mycobacterium 
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intracellulare 7802/2017, Mycobacterium abscessus ssp. abscessus 180/2018, M. kansasii 
1959/2018 and Mycobacterium chelonae 16/2018 have been established. 
The calculated distribution of the main MA types is based on the MA specimens listed in 
Table 4 (Materials and Methods). The α-C78 was found to be the most abundant MA in all 
the included MTBC strains, however in the case of MTBC-1/2015, it was equally 
represented with the m-C85 MA. The second most represented MA was the α-C80 in the 
case of MTBC-242/2000, MTBC-254/2000 and MTBC-3910/2014 and m-C85 in MTBC-
1/8508/2014. An other methoxy-MA, the m-C87 was also highly represented in most of the 
cases, with the exception of MTBC-1/8508/2014. α-C82, m-C88, k-C87 and m-C89 were 
also represented in higher, than 5% in 4 out of the 5 analysed strains, although the latter one 
was hardly detected in MTBC-1/8508/2014. Most of the keto-MAs, except k-C87, 
distributed in a low level, however k-C84 was found to be present in a high ratio in one 
strain, namely in MTBC-1/8508/2014. The clinical isolates MTBC-254/2000, MTBC-
3910/2014 and MTBC-242/2000 provided rather similar MA profile, while the lipid 
composition of MTBC-1/2015 and especially MTBC-1/8508/2014 represented an exception 
in many aspects. 
 
Figure 25: MA profiles of 5 MTBC strains, isolated from patients 
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Similar results were described by Borowska-Strugińska and colleagues (2014) and Bhamidi 
and colleagues (2011). Both team described α-C78 MA as the most represented one, 
however the former team find the α-C80, m-C87, m-C85 highly represented, respectively, 
while in the latter study the abundance of α-C78 was followed by m-C85, m-C87, α-C80, 
respectively, although both profiles were acquired from the M. tuberculosis H37Rv strain. 
The profile regarding the α-C82, k-C87, m-C89, m-C88, k-C86, α-C84 and k-C88 MAs were 
similar. In our calculated MTBC-average profile α-C82 and k-C86 were equally represented, 
followed by k-C84, k-C87, m-C89/m-C88, α-C84 and k-88, respectively. 
Considering the summarised values of individual MA-s based in their type the α-MAs were 
represented in the highest ration in 4 strains, namely in MTBC-254/2000; MTBC-
3910/2014; MTBC-242/2000; and MTBC-1/8508/2014 (Figure 26), ranging between 40%-
50%. The highest summarised area values in the MTBC-1/2015 strain belonged to methoxy-
MA specimens, which were slightly less represented in the other 4 strains, adding up to 
approximately 40% of the overall area values. The least represented MA type was the keto-
MA in every cases. The high representation of α-MAs in considered to be typical in the case 
of slow growing mycobacteria (Laval et al., 2001), although it does not have any diagnostic 
value in itself, as for example in the case of M. bovis BCG strain the summarised keto-MAs 
were find to be the most represented (Yoshino et al., 2019). In the experiment of Bhamidi 
and colleagues (2011) the relative ratios of the MA types, derived from M. tuberculosis 
H37Rv, were almost identical with the above described results, including 9 α-, 9 methoxy 
and 7 keto-MA specimens. Summarising the published abundance in per cent form published 
by Borowska-Strugińska and colleagues (2014), in their study α-MAs were present in 45%, 
methoxy-MAs in 37%, keto-MAs in 18%. Regarding the reference strain used for diagnosis 
of TB infection in ancient human bone material Hershkovitz and colleagues (2008) 
published the following per cent distribution: α-MAs were represented in 48%, methoxy-




Figure 26: The distribution of the 3 main MA types in the 5 MTBC strains, isolated from patients 
The MA profiles of M. kansasii 1959/2018, Mycobacterium gordonae 389/2018, 
Mycobacterium intracellulare 7802/2017, Mycobacterium abscessus ssp. abscessus 
180/2018 and Mycobacterium chelonae 16/2018 draw a more diverse picture (Figure 27). 
The most abundant MA specimen was the α-C78 MA similarly to the analysed MTBC 
strains, however, its distribution was much higher among the included NTM species. The 
second most abundant MA was the α-C80, with the exception of M. intracellulare 
7802/2017, in which case the representation of α-C80 was the most prominent compared to 
α-C78. The α-C82 was detected in all the analysed cases. The abundance of the individual 
methoxy- and keto-mycolates is very various. The m-C85 MA was represented in 10% or 
above in the case of M. kansasii 1959/2018, M. gordonae 389/2018 and M. abscessus ssp. 
abscessus 180/2018, and being present with 5% abundance in M. intracellulare 7802/2017. 
All the other methoxy-MA specimens were represented in less than 5%, with the exception 
of m-C87 presenting 9% abundance in M. abscessus ssp. abscessus 180/2018 and 6% 
abundance in M. kansasii 1959/2018. Among the included keto-MAs k-C84 was represented 
in 6% and 5% in the case of M. kansasii 1959/2018 and M. gordonae 389/2018, respectively, 
furthermore, k-C87 had 8% abundance in M. kansasii 1959/2018. All the other not described, 




Figure 27: MA profiles of 5 NTM strains, isolated from patients 
In the study published by Szewczyk and colleagues (2013) α-C78, α-C80, α-C82, α-C84, m-
C85, k-C86, k-C87 and m-C87 were monitored and the following NTM species were 
included: M. kansasii, M. intracellulare, M. abscessus and M. avium. According to their 
findings the most abundant MA specimen was the α-C78 in every cases. In M. kansasii m-
C85 was also highly represented, with 39% abundance. The abundance of α-C80, α-C82 and 
k-C87 was calculated to be 1.11%, 1.13%, 1.81% respectively, the other monitored MA 
specimens were represented in less than 1% each. During the analysis of M. intracellulare 
α-C78 represented the 98% of overall abundance, meanwhile the abundance regarding the 
rest of the MAs were below 1%, moreover k-C86 was not detected at all. In the case of M. 
abscessus α-C78 was registered with 98% abundance, all the other monitored MAs were 
represented in less than 1% of the overall distribution, each. Based on the published mass 
spectra profile of Shui and colleagues (2011) in M. kansasii the most abundant peak belonged 
to α-C80, followed by k-C85 (this MA not included in our analysis, but it was detected during 
the analysis). Peaks belonging α-C78 and k-C87 were highly abundant, appearing with 
nearly the same intensity and α-82 was also detected. On the mass spectrum of M. gordonae 
among those MAs, which are included in our analysis the presence of α-C78 and α-C80 
(respectively to their abundance) can be observed. In the case of M. abscessus and M. 
chelonae they have detected the total lack of oxygenated MA species, moreover the abundant 
α-MAs had shorter alkyl-chain than the ones included in our study. Song and colleagues 
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(2009) analysed the MA profile of several mycobacteria based on the length of their α-chain. 
Their study involved M. intracellulare and according to their published mass spectrum α-
C78, α-C80 and α-C82 were the most abundant MA specimens, beside m-C68. In the case 
of M. gordonae a broader variety of MAs were detected, namely the m/k-C81, m/k-C83, 
m/k-C85, α-80, α-78 being the most abundant, beside smaller MAs, which were not included 
in our study, such as α-C76, α-C74, m/k-C76, m-C81, m/k-C82.  
Considering the summarised values of individual MA-s based in their type in the analysed 
NTM species a distinct distribution can be observed, compared to MTBC. Although the 
highest abundance belongs to the α-MAs in these cases, as well, the oxygenated MA-s are 
less or hardly even represented (Figure 28). In every cases α-MAs were more than 60% 
abundant. In M. kansasii 1959/2018 mycolates belonging to α-MAs gave a bit more, than 
the 60% of all MA area values, followed by methoxy- and keto-MAs, which represented the 
21% and 17%, respectively. In M. chelonae keto-MAs were absent, and the overall methoxy-
MAs were represented in less than 1%. The abundance of α-MAs of M. gordonae 389/2018 
was 80%, meanwhile methoxy- and keto-MAs were distributed in 12% and 7%, respectively. 
The extracted MAs of M. intracellulare 7802/2017 consisted α-MAs in 88%, methoxy-MAs 
in 9% and keto-MAs in 2%. The MA profile of M. abscessus ssp. abscessus 180/2018 based 
on 65% α-MAs, 28% methoxy-MAs and 7% keto-MAs. 
In contrast, the detailed review about mycobacterial lipids published by Minnikin and 
Brennan (2020) suggests that in the members of M. avium complex (e.g. M. intracellulare) 
methoxy-MAs are replaced by wax-ester MAs, moreover MAs of M. chelonae and M. 
abscessus contain only comparable amounts of α- and shorter alkyl-chain α’-MAs, which 
were not included in our investigations. The aforementioned differences in our results 
implies the need of further investigation of these NTM strains and the re-consideration of 




Figure 28: The distribution of the 3 main MA types in the 5 NTM strains, isolated from patients 
6.1.2.6 Optimisation of a new eluent composition for combined detection of MAs and MCs 
As the above discussed examples present, the comparison of lipid profiles belonging to NTM 
species has limits. It can be implicated from the different sample set (e.g. clinical isolates or 
reference strains), the different sample pre-treatment protocols and depends on the used 
instrumentation, since the numerous approaches are available. In our results the oxygenated 
MA-s were more represented in the NTM species, as the aforementioned literature would 
imply. For the support of our results, a new method was developed, capable of the separation 
and detection of mycocerosates and MAs. Firstly the following eluent composition was 
tested without and with 3 commonly used additives (5mM ammonium formate; 0.1% acetic 
acid; 0.1% formic acid): MeOH:ACN:CHCl3:IPA (6:1:0.5:2.5). With the application of the 
standard eluent without any additives all the monitored MAs provided recognisable peaks 
(Figure 29.1). The same eluents composition, supplemented with 5mM ammonium formate 
provided similar results, however a slight, approximately 30%, increase was noted in the 
area values (Figure 29.2). With the application of 0.1% acetic acid with the exception of α-
C78 MA the area value of all the target molecules increased, especially in the case of the 
oxygenated MAs (Figure 29.3). The integrated area of α-C80, m-C85, k-C86, k-C87, m-C87 
were 1.3; 1.6; 2 and 3 times larger, respectively. The same eluent composition supplemented 
with 0.1% formic acid resulted a decreased ionisation of MAs (Figure 29.4). An other, more 
non-polar eluent composition was also tested with the two additives, which presented 
positive effect in the previous comparison. The eluent consisted IPA:heptane:ACN (4:1:5), 
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and was tested first with the addition of 0.1% acetic acid and 5mM ammonium formate. In 
the former case a great increase of the detected peaks was observed. In the case of α-C78, 
m-C85, k-C86 and k-C87 an increase up to 250% was achieved, while the are values of α-
C80 and m-C87 presented 5 times increase (Figure 29.5). The addition of 5 mM ammonium 
formate to this eluent composition resulted 50% decrease in the integrated are values (Figure 
29.6). 
 
Figure 29: Optimisation of a less polar eluent composition 
6.1.3 Mycocerosic acid separation and detection by Q-Exactive Plus Orbitrap MS 
Firstly, the possibility of MC-MA separation was tested on a Gemini – NX C18 column with 
the previously selected eluent composition (eluent A was MeCN, containing 0.1% AcOH 
(AcOH), eluent B consisted of IPA:heptane (8:2), supplemented with 0.1% AcOH). The 
separation was carried out with gradient elution starting at 10% B eluent, and was increased 
according to the following steps: 0 min 10% B, 5 min 15% B, 15 min 70% B, 16 min 90% 
B, 18 min 90% B, 18.5 min 20% B, 19.5 min 20% B, 20 min 90% B, 23 min 90% B, 24 min 
10% B and 28 min 10% B. For the analysis lipids were extracted from M. tuberculosis 
1/2015. 
On the combined extracted ion chromatograms (EICs) both lipid biomarkers were observed 
(Figure 30). Due to the much shorted alkyl-chain of mycocerosic acids, their retention time 
was shorter compared to the mycolic acids. The targeted mycocerosic acids (Table 7) eluted 
between 6 and 10 min, while MAs were detected between 15-16 min. During the 
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chromatographic run the first eluting component was the C27 mycocerosic acid (Rt: 6.26), 
the second was the C29 (Rt: 7.81), followed by C30 (Rt: 8.13), C32 (Rt: 9.37) and C33 (Rt: 
9.52), respectively. The recorded mycobacterial mycocerosate HPLC profiles, correspond 
well with those recorded previously by NI-CI GC-MS of PFB esters (Lee et al., 2012; 
Redman et al., 2009; Donoghue et al., 2017). In comparison, the C29 and C30 MCs co-
chromatographs with the application of the GC-MS method. In the HPLC measurement, the 
additional carbon in the C30 MC ensures that it is retained longer by the reverse phase 
column media, subtle structural differences being less influential in the liquid phase. A 
similar relationship can be observed for the C32 and C33 MCs. 
Despite of this highly non-polar solvent composition the elution of MAs was not complete, 
especially in the case of MAs with longer alkyl-chain length (e.g. k-C86, k-C87).  
 
Figure 30: Combined EIC of MCs and MAs 
As our aim was to develop a simple, but sensitive method for TB diagnostics on 
archaeological samples, we could not afford even a minimal carry-over during our 
measurements. However, there is a possibility that with further changes on the method we 
could have overcome with this issue, we chose to prioritise working only with MCs, since 
this lipid group is represented in a more limited group of mycobacteria (See Chapter 3.6).  
6.1.3.1 Comparison of APCI and ESI ion sources for mycocerosic acid detection 
First of all, we compared the efficiency of ESI and APCI ion sources for MC detection, the 
two most commonly used ion sources in the case of HPLC-MS based lipid analysis 
(Byrdwell, 2001; Nichols & Davis, 2002; Willmann et al., 2011; Zhu et al., 2013; Horai et 
al., 2019). The literature implies that, although APCI is suitable to examine several kinds of 
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lipids and provides a relatively simple mass spectrum, it can certainly lead to the degradation 
of labile lipids. In contrast, beside the extremely high-sensitivity and good reproducibility, 
which can be achieved with ESI, it provides a softer ionisation and minimises the undesired 
in-source fragmentation (Koivusalo et al., 2001; Crane et al., 2012; Han et al., 2012; Yunker 
et al., 2014; Wang et al., 2015b).  
Initially, the MS parameters were tuned with both ion sources (Váradi et al., 2020). The 
optimisation was carried out in FIA mode with 50% of both eluent A and B. The basic 
settings of the spray voltage and S-lens voltage were 4kV and 60 V, respectively. It was 
found that increasing the capillary temperature from 300 °C to 350 °C increased the intensity 
approximately to 150% (Figure 31.1 and 31.2). As the auxiliary gas temperature even in the 
previous measurements affected the ionisation positively, it was increased from 300 °C to 
350 °C. This change implied a 120% increase in the integrated area values (Figure 30.1 and 
30.3). When both the capillary and the auxiliary gas temperature was set to 350 °C the 
intensity of the monitored peaks were doubled compared to the initial values (Figure 31.1 
and 31.4). Next, the application of APCI as ion source had been tested. Despite of the high 
increase of the basic capillary temperature from 250 °C first to 350 °C (Figure 31.5 and 31.6) 
and then up to 400 °C only a very low rise of the intensity was observed (Figure 31.6 and 
31.7), hence further optimisation steps did not seem to provide promising results. After 
finding the application of HESI ion source to be more effective, the S-lens voltage, was also 
optimised. Its increase from 60 V to 70 V caused approximately 1.3 times increase in the 
intensity (Figure 31.4 and 31.8). Considerable gain in the intensity was not gained by further 
increase of this parameter (Figure 31.8 and 31.9). With the optimal settings of the MS 
(capillary and the auxiliary gas heated to 350 °C, the spray voltage set to 4 kV, the S-lens 
voltage set to 70 V) the intensity of C27 MC grew with180%, the final intensity of C29-C32 




Figure 31: Comparison and optimisation of APCI and ESI ion sources 
6.1.3.2 Confirmation of the mycocerosic acid peaks and the development of mycocerosic 
acids profiles from standard mycobacteria 
After the retention times had been observed, with the application of the described gradient 
elution, the divert valve was set to switch to be open in the direction of the MS only from 5 
to 15 min to avoid the contamination of the instrument (Váradi et al., 2020). During the 
evaluation, the detected MC peaks have been normalised to the peak with the highest area 
value. Beside the similarities with the observed elution patterns in the previously published 
methods (Redman et al., 2009; Lee et al., 2012; Donoghue et al., 2017), we compared the 
chromatogram of several mycobacateria (MTBC and NTM). Those peaks which were 
observed only in those strains (e.g. MTBC, M. kansasii), which are described as 
mycobacteria able to express mycocaerosates, but not in the other strains, were considered 
as MC peaks. 
In the case of M. tuberculosis H37Rv strain, the C32 (100%) MC is the most abundant, 
followed by C29 (57%) and C30 (50%) MCs, with C27 (9%) and C33 (8%) as minor 
components (Figure 32) (Váradi et al., 2020). The highest RSD was determined for the C27 
MC (28%), while C29 and C33 MCs showed 12% and 5% RSD, respectively; the lowest 




Figure 32: MC profile M. tuberculosis H37Rv 
The MC profile of M. bovis (ATCC, NR-31210) was also established (Váradi et al., 2020). 
The C29 MC has been presented in the highest ratio (0% RSD). It was followed by the C27 
and C32 MCs with 30 and 28% (10 and 20% RSD, respectively). The least presented MCs 
were C30 and C33 MCs, and their area value was 21% and 2% of the highest peak (14 and 
13% RSD, respectively) (Figure 33). 
 
Figure 33: MC profile M. bovis (ATCC) 
To give a generally applicable reference MC profile, the average M. tuberculosis profile was 
established by the examination of five MTBC strains deriving from patients (Váradi et al., 
2020). The M. tuberculosis complex 1/8508/2014 strain has been excluded from the 
calculation of the average M. tuberculosis profile establishment, as its profile resembled that 
of the M. bovis strain provided from BEI Resources (Figure 33 and Figure 34 E) and with 
the published M. bovis values (Redman et al., 2009). The most well-marked difference of 
this strain is that C29 MC was most prominent (0% RSD), while C32 was only 22% (18% 





Figure 34: MC profiles of the analysed clinical MTBC samples 
The rest of the analysed MTBC isolates provided rather similar profiles (Váradi et al., 2020). 
In every case C32 MC was the most prominent, while C29 and C30 MCs were present with 
similar distribution in the case of MTBC-1/2015, MTBC-242/200 and MTBC-3910/2014 
strains, with a slightly higher representation of C29 (Figure 34 A, B, D). The dominance of 
C29 MC was more expressed in the strain, MTBC-254/2000 (Figure 34 C). Regarding the 
average distribution C29 and C30 were represented in 31% and 23%, respectively (Figure 
34F). The C33 MC was observed in the lowest ratio in every cases, reaching only 2% of C32 
in the calculated average profile. The relative proportions of these M. tuberculosis MCs are 
in general accord with previously published profiles (Redman et al., 2009; Minnikin et al., 
1993). The observed EICs presented a similar pattern with those in those in M. tuberculosis 
H37Rv (Figure 32 and Figure 35). Within the m/z range of C27 MC (409.40510) three peaks 
appeared in the case of M. tuberculosis H37Rv, MTBC-242/2000, MTBC-254/200 and 
MTBC-3910/2014 (Figure 35 B, C, D). During the comparison of all examined strains, the 
second peak was exclusively observed in mycobacterial strains expressing MC (Figure 35). 
In the mycolic acid profiling analysis two strains exhibited relevant differences, namely the 
MTBC-1/2015 and MTBC-1/8508/2014. The C27 MC peak appeared solitaire in MTBC-
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1/8508/2014 and M. kansasii-1959/2018 (similarly to the chromatogram of M. bovis ATCC, 
Figure 33), and was eluting along a later peak in MTBC-1/2015. 
 
Figure 35: EIC of the analysed MTBC strains and M. kansasii-1959/2018 
During the examinations of NTM isolates, in the case of M. kansasii-1959/2018, the C30 
MC was recorded in the highest ratio (0% RSD) (Váradi et al., 2020). It was followed by the 
C29 (38%, 14% RSD) and C32 MC (30%, 7% RSD), while the C27 and C33 MCs were 




Figure 36: MC profile of M. kansasii 1959/2018 
Among the rest of the NTM species (Figure 37), a peak co-chromatographing with C27 MC 
was seen in the M. avium strain, but the other monitored MCs were not detectable; the true 
identity of this component remains to be established (Váradi et al., 2020). The remainder of 
the examined NTM species did not show any traces of the monitored MCs (Figure 37). These 
results correlate well with previously published data, which point to the fact that MCs can 
be found only in the following species: M. tuberculosis, M. bovis, M. gastri, M. 
haemophilum, M. kansasii, M. leprae, M. marinum, and M. ulcerans (Redman et al., 2009; 
Minnikin et al., 1985; Daffé & Lanéelle, 1988; Draper et al., 1983; Hartman et al., 1992; 
Minnikin et al., 1993). An extended study presenting a THM-GC-MS based method for the 
differentiation of M. tuberculosis from NTM species came to a similar result (Dang et al., 
2013). In this study, the applied MC biomarkers have not been detected in the following 
NTM species: M. avium 16229/2018 (Figure 37 C), M. chelonae 16/2018 (Figure 37 D), M. 
intracellulare 7802/2017 (Figure 37 E), M. fortuitum 3/2018 (Figure 37 F), M. gordonae 
389/2018 (Figure 37 G), M. abscessus 180/2018 (Figure 37 H) and M. chimaera 619/2018 
(Figure 37 I). The MC profile from M. kansasii 1959/2018 (Figure 36) includes significant 
proportions of C32 MCs, which correlates with its perceived role as an ancestor of the broad 




Figure 37: EIC of the analysed NTM species along with EIC of MTBC for reference 
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6.1.3.3 Profiles of mycocerosic acids from the analysed Vác mummies 
With the application of the optimised method, which was used to establish the previously 
introduced profiles we tested our method on samples derived from Vác mummies, diagnosed 
with TB infection on the base of aDNA analysis (Váradi et al., 2020). The targeted MCs 
were recorded in SIM. The individual EICs are grouped on Figure 38 and Figure 40). 
 
Figure 38: The EICs of the positive Vác mummy samples 
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The lipid profiles observed for the extracts of both rib and soft tissue samples from four 
consistent cases are shown in Figure 38. The M. tuberculosis C27 MC minor component 
(Figure 32 and Figure 34) was not detected in any of these extracts (Váradi et al., 2020). The 
results for the samples taken from the remains of Terézia Hausmann (#68) were positive. In 
the MC profile for the soft tissue sample (Figure 38 B and Figure 39), the main C32 peak 
was accompanied by major C29, C30 and minor C33 peaks. The rib sample (Figure 38 A 
and Figure 39) had clear main C32 and major C30; however, any minor C33 was indistinct 
and the area for expected C29 was obscured. The positive rib and soft tissue profiles, from 
the remains of Anna Schneller (#78) (Figure 39 A, B and Figure 38), both had the expected 
main C32 and major C29 and C30, but the minor C33 was not so clear. Both types of samples 
belonging to Erzsébet Virágh (#80) (Figure 38 E, F and Figure 39) proved to be also positive, 
with clear C29, C30, C32 and C33 peaks being detected; however, the C33 peak in case of 
the soft tissue sample was overrepresented, a rather broad peak suggesting overlap with an 
unknown component (Figure 38 F and Figure 39). The rib and soft tissue of László Beniczky 
(#121) (Figure 38 G, H and Figure 39) exhibited clear MC peaks for C30 and C32 
mycocerosates, with little C33. The C29 signals were questionable, as the rib peak (Figure 
38 G and Figure 39) was not fully resolved, and in the soft tissue extract, the peak shape was 
atypical (Figure 38 H and Figure 39). 
 




The soft tissue samples of Gáspár Steitel (#25) did not contain detectable MCs (Figure 40 
B), while the rib extracts (Figure 40 A) showed very weak indecisive results for C30 and 
C32 MCs (Váradi et al., 2020). Conversely, the rib extracts from Terézia Damiani (#79) 
(Figure 40 C) were devoid of MCs, but the soft tissue samples (Figure 40 D) provided barely 
discernible indications of C30 and C32 MCs. These inconclusive results cannot be regarded 
as a positive indication of tuberculosis in these mummies, but the fact that the very weak 
signals are for two of the principal MC components (C30 and C32) may be useful signposts.  
 
Figure 40: The EICs of the negative Vác mummy samples 
It can be concluded that when the three most presented C32, C30, and C29 MCs, with a 
principal amount of the C32 component, are found in archaeological samples, infection with 
M. tuberculosis is indicated (Váradi et al., 2020). Compliance with these requirements was 
recorded for the rib and soft tissue samples from Terézia Hausmann (#68), Anna Schneller 
(#78), Erzsébet Virágh (#80) and László Beniczky (#121) (Figure 5). However, the cases of 
Gáspár Steitel (#25) and Terézia Damiani (#79) (Figure 6) cannot be recognised as positive. 
In most cases, C32 MC was presented at least in a double ratio compared to the C30 MC, 
except for case #68 soft tissue, where the C30 and C32 mycocerosates were found in almost 
equal ratios (Figure 5 B). Only traces of C33 mycocerosic acid were detected from both 
sample types of #68, #78, and #80, as well as from the soft tissue sample of #121, so the 
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diagnostic use of this biomarker is limited for ancient tuberculosis. However, C33 and C34 
mycocerosic acids have established value for recognising ancient Mycobacterium leprae, 
including joint tuberculosis-leprosy cases (Masson et al., 2015). 
The selected individuals were examined initially by Fletcher and colleagues (Fletcher et al., 
2003). In their analysis the presence of the 123-bp region of the IS6110 insertion sequence 
was screened. Samples providing positive samples were further analysed for silent point 
mutations of the gyrA 95 and katG 463 genes. Based on the detected silent point mutatations 
the differentiation of the infectious agents into three genotypes was carried out, following 
the work of Sreevatsan and colleagues (1997). In a later study the mummy of Terézia 
Hausmann was the subject of the first metagenomic determination by Chan and colleagues 
(2013), followed by a more comprehensive whole genomic study by Kay and co-workers 
(2015). Correlations of lipid and DNA biomarkers are summarised below for each individual 
mummy. 
Terézia Hausmann (#68). Positive MC profiles (Figure 38 A, B) matched the result of the 
DNA-based analysis; traits of gyrA 95 and katG 463 genes were found in the chest, with the 
silent point mutations characteristic to the group 3 genotype of M. tuberculosis (Fletcher et 
al., 2003). Metagenomic analysis found a multiple infection by more than one M. 
tuberculosis strain (Chan et al., 2013). Later investigations of a left lung specimen revealed 
that one of the M. tuberculosis strains belonged to sublineage 4.1.2.1, also known as the 
Haarlem lineage (Kay et al., 2015; Stucki et al., 2016), and the other one belonged to the 4.7 
sublineage (Kay et al., 2015). The latter one is recently identified as the part of sublineage 
4.10 (Stucki et al., 2016). 
Anna Schneller (#78). Amplification of the katG 463 codon from a rib sample by Fletcher 
and colleagues (2003) gave good support to the positive MC profiles (Figure 38 C, D). Based 
on its sequence, the infectious agent could belong to the group 2 or group 3 genotype. A later 
phylogenetic analysis revealed that the M. tuberculosis strain also belonged to the current 
MTBC sublineage 4.10 (Kay et al., 2015; Stucki et al., 2016).  
Erzsébet Virágh (#80). Similarly, Fletcher and colleagues (2003) found that, based on the 
silent point mutations of gyrA 95 and katG 463 genes, the infectious agent belongs to the 
group 3 genotype. The full genomic examinations by Kay and colleagues (2015) also 
revealed that the M. tuberculosis strain belongs to the 4.1.2.1 sublineage. All this evidence 
backs the positive coherent MC profiles (Figure 38 E, F).  
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László Beniczky (#121). The MC profiles had slightly decreased positivity due to 
questionable C29 peaks (Figure 38 G, H), but diagnostic PCR products have been amplified 
earlier from a pleura sample, with a silent point mutation pattern belonging to group 3 
(Fletcher et al., 2003). Positive sequencing data of a rib sample showed a mixed infection of 
M. tuberculosis sublineage 4.10, sublineage 4.3 and Lineage 4 (Kay et al., 2015; Stucki et 
al., 2016).  
Gáspár Steitel (#25). Unfortunately, the MC profiles were essentially negative (Figure 40 A, 
B) in contrast with the previous detection of M. tuberculosis complex DNA (Fletcher et al., 
2003; Kay et al., 2015). The first PCR based aDNA examinations, using a sample taken from 
the left chest, detected only the traits of katG 463 gene, with the silent point mutation 
suggesting that the infectious agent belonged to group 2 or 3 (Fletcher et al., 2003). The later 
metagenomic examinations of tissue from the abdomen region determined that the M. 
tuberculosis strain belongs to the Lineage 4 (Kay et al., 2015) 
Terézia Damiani (#79). In this case, the monitored MC biomarkers could not be detected 
(Figure 40 C, D). However, Fletcher and colleagues (Fletcher et al., 2003) amplified the 
fragment of the katG 463 gene in the sample taken from the pelvis region of this individual 
and found the silent point mutation characteristic of group 2 and 3. Metagenomic analyses 
have not been performed on extracts of this mummy. 
Overall, in four of the six mummies studied, there is good correlation of mycocerosate 
profiles (Figure 39) with positive ancient DNA analyses. In the two cases lacking significant 
mycocerosate presence (Figure 40), but with good indications of aDNA biomarkers, the 
discrepancy may be due to differences in the samples investigated. Mummified individuals 
provide a much greater choice of areas for sampling than in skeletons without soft tissue. 
Even though the cases of Gáspár Steitel and Terézia Damiani (Figure 40) were deemed 
negative, the very weak signals observed in Figure 40 A, D could be sufficient to encourage 









A variety of analytical methods have been employed for mycobacterial lipid biomarker 
profiling (Donoghue et al., 2017). Fluorescence HPLC is well-developed for the analysis of 
mycolic acids and phthiocerols (Hershkovitz et al., 2008; Lee et al., 2012; Donoghue et al., 
2017). Furthermore, there is only one isolated case of direct mass spectrometric detection of 
M. tuberculosis free mycolic acids from a Neolithic lesions vertebra (Borowska-Strugińska 
et al., 2014). Mass spectrometry, however, has been the basis of the analysis of ancient 
mycocerosic acids, using selected ion monitoring, negative ion-chemical ionisation GC-MS 
of pentafluorobenzyl ester derivatives (Redman et al., 2009; Lee et al., 2012; Donoghue et 
al., 2017). However, this method is a well-proven procedure, the popularity and availability 
of the necessary instrumentation have declined over the past two decades. Conversely, 
HPLC-MS facilities have become routine in biological and other analytical laboratories, thus 
our aim was to establish a lipid biomarker based HPLC-HRMS method, for TB diagnosis in 
historical human samples, as this instrumentation is available in many laboratories, and has 
the potential of a rapid, but sensitive and at the same time affordable measurement protocol. 
 
The most important achievements of our study are summarized as follows: 
1. The first step towards establishing a lipid biomarker based HPLC-HRMS method for 
TB diagnosis in historical human samples was the tuning of the applied HPLC and the 
MS parameters, for the efficient detection of mycolic acids and mycocerosic acids and 
the optimisation of the sample pre-treatment process. In the case of the MA detection 
method development 5 different eluent compositions were tested on the single 
quadrupole LCMS system, and 14 eluent compositions on the HPLC-Orbitrap MS 
system. The application of non-polar solvents is widespread in HPLC-MS based MA 
detection methods, which is most commonly chloroform (Bhamidi et al., 2011; Shui et 
al., 2012; Szewczyk et al., 2013; Borowska-Strugińska et al., 2014; Portevin et al., 
2014). In our initial measurements on the single quadrupole LCMS system the 
application of chloroform seemed beneficial. The presence of increased chloroform 
concentration affected negatively the ionisation of MAs on the Orbitrap MS. With the 
application of heptane, as non-polar component we could increase the peak intensity, 
moreover we were able to establish a method for the separation and parallel detection 
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of MAs and MCs. The MS parameters were optimised with 1 eluent composition on the 
single quadrupole LCMS system, and with the application of 2 eluent compositions on 
the HPLC-Orbitrap MS system for MA detection. MS parameters were tuned and with 
the application of 1 eluent composition for MC detection. During the optimisation of 
the MS parameters, the positive effect of the increased capillary and auxiliary gas 
temperature, as well as the increased capillary and S-lens voltage was observed. The 
intensity of the targeted peaks become higher regardless of the applied solvent 
composition. During the optimisation of the MC detection protocol APCI and ESI ion 
sources were compared, both commonly used in lipid detection (Byrdwell, 2001; 
Nichols & Davis, 2002; Willmann et al., 2011; Zhu et al., 2013; Horai et al., 2019). For 
the detection of mycocerosic acids ESI has been observed as more efficient ion source, 
which is known to provide softer ionisation in contrast with the APCI (Yunker et al., 
2014). As for the optimisation of the sample pre-treatment protocol of MA extraction 
the KOH concentration of the initial saponification mixture was tested. The comparison 
of 20% or 30% KOH content did not presented any difference, however, further 
decrease to 10% resulted lower MA outcome. Beside the optimisation of KOH 
concentration, 5 different extraction solvents/solvent combinations were compared. The 
results suggested that nonetheless the application of non-polar solvents are needed for 
the extraction, the lowest polarity is not equal with the best efficiency. 
2. With the application of the optimised methods, the development of lipid profile library, 
regarding both mycolcic and mycocerosic acids has been carried out. The MA profiles 
of 5 MTBC clinical isolates (MTBC-1/2015; MTBC-254/2000; MTBC-3910/2014; 
MTBC-242/2000; and MTBC-1/8508/2014) and 5 NTM clinical isolates (M. gordonae 
389/2018, M. intracellulare 7802/2017, M. abscessus ssp. abscessus 180/2018, M. 
kansasii 1959/2018 and M. chelonae 16/2018) have been established. However, data 
regarding MA profiles of NTM species in the literature presents a higher variety (Song 
et al., 2009; Shui et al., 2011; Szewczyk et al., 2013), and our sample set is not adequate 
for statistical conclusions, with the low representation of oxygenated mycolates the 
differentiation of MTBC from NTM representatives seems possible with the application 
of lipid profiling via HPLC-MS, but the confirmation requires the extension of the 
library. The MC profile development included 5 MTBC clinical isolates (MTBC-
1/2015; MTBC-254/2000; MTBC-3910/2014; MTBC-242/2000; and MTBC-
1/8508/2014), M. tuberculosis H37Rv and M. bovis (ATCC) reference strains and 8 
NTM clinical isolates (M. avium 16229/2018, M. chelonae 16/2018, M. intracellulare 
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7802/2017, M. fortuitum 3/2018, M. gordonae 389/2018, M. abscessus sp abscessus 
180/2018, M. chimaera 619/2018, M. kansasii 1959/2018). Among the representatives 
of MTBC in 4 out of 5 strains and in the case of M. tuberculosis H37Rv reference strain, 
the same tendency of MC distribution has been observed as the literature is suggesting 
for M. tuberculosis (Redman et al., 2009; Lee et al., 2012). One of the 5 strains presented 
a MC distribution more characteristic to M. bovis. Among the analysed NTM species 
only the profile of M. kansasii was established, as the remainder species are not 
expressing mycocerosates. The analysed M. avium strain presented a peak with the same 
retention time of C27 MC, which will need further investigation. Based on the observed 
profiles the detection of prominent C32 MC content, accompanied with significant C29 
and C30 MC peaks were used as criteria for MTB diagnosis in the following analysis. 
3. The efficiency of the established lipid biomarker based method was tested on a well-
studied collection of mummified human remains, namely on the Vác mummy collection. 
Regarding the MA detection, despite of the applied non-polar solvent composition the 
elution of MAs was not complete. We could not afford even a minimal carry-over during 
our measurements, hence only the MC method was tested on the mummy samples. In 
the case of four mummified individuals, profiles of characteristic M. tuberculosis MCs 
were recorded, but two other mummies did not yield diagnostic MC profiles. However, 
all the mummy samples had been found, previously, to be positive by aDNA 
examination, but the samples in this study were not identical with those used previously 
and the sampling site may affect the results. An extended study of confirmed cases, with 
multiple sampling sites of skeletal material and soft tissue, where available, is suggested 
to clarify the situation. The present results, however, provide further confirmation of 
widespread tuberculosis in the Vác mummies. The HPLC-ESI-MS method, developed 
for the detection of MCs, opens up a new avenue for the detection of ancient 
mycobacterial disease, encompassing both tuberculosis and leprosy and joint cases. 
Currently, the instrumentation required is available in many laboratories and technical 
developments are likely to reduce complexity and increase sensitivity and affordability. 
A particular advantage is that no chemical derivatisation of the particular lipid 
biomarkers is needed, the free acids being utilised. The method could be extended to 
include the related M. tuberculosis lipid biomarker, mycolipenic acid (Donoghue et al., 
2017). However, in our method we could not overcome with the carry-over of MAs yet, 
involving new solvent compositions and testing new approaches for separation, a 
comprehensive protocol could be developed to add profiles of free mycolic acids 
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(Borowska-Strugińska et al., 2014; Donoghue et al., 2017). In the well-established 
fluorescence HPLC procedure, the recognition of diagnostic mycolate profiles requires 
extensive derivatisation and sequential reverse and normal phase HPLC analyses 
(Hershkovitz et al., 2008; Donoghue et al., 2017). In contrast, in a single selected ion 
monitoring HPLC run, all the diagnostic mycolic acid data are collected and are 




The diagnosis of ancient mycobacterial disease in archaeological material requires a 
multidisciplinary approach. Most of the TB-related bony lesions are the result of extra-
pulmonary TB (Aufderheide & Rodríguez-Martín, 1998; Marcsik et al., 1999, 2009; Pálfi & 
Marcsik, 1999; Hershkovitz et al., 2002; Maczel, 2003; Ortner et al., 2003; Paja et al., 2015; 
Pálfi & Molnár, 2009; Pálfi et al., 2012; 2015; Mariotti et al., 2015; Spekker, 2018; Spekker 
et al., 2018; Spekker et al., 2020a; Spekker et al., 2020b), which was registered only in 16% 
of all incident cases in 2019 (WHO, 2020). Moreover, only a low proportion of 
extrapulmonary TB develops specific and detectable bony lesions. Macromorphological 
paleopathological studies lead necessarily to the underestimation of ancient TB prevalence. 
For the better estimation of TB incidence in past populations an array of specific biomarkers 
can be brought into play to confirm initial skeletal diagnoses and search in the soft tissue of 
suspected cases (Donoghue et al., 2017). The pioneering application of whole-genome 
sequencing (Chan et al., 2013) has opened the prospect of obtaining comprehensive 
information regarding the nature and number of infecting M. tuberculosis strains (Kay et al., 
2015; Bos et al., 2014). Confidence in aDNA diagnoses has been greatly reinforced by 
recording profiles of specific lipid biomarkers, which are particularly robust and accessible 
(Donoghue et al., 2017). Initial lipid targets were the C70 to C90 mycolic acids (Gernaey et 
al., 1998; Donoghue et al., 1998; Hershkovitz et al., 2008), but the range was broadened to 
include the mycocerosic and C27 mycolipenic acids (Redman et al., 2009; Lee et al., 2012) 
and phthiocerols (Lee et al., 2012). 
A variety of analytical methods have been employed for mycobacterial lipid biomarker 
profiling (Donoghue et al., 2017). Fluorescence HPLC is well-developed for the analysis of 
mycolic acids and phthiocerols (Hershovitz et al., 2008; Lee et al., 2012; Donoghue et al., 
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2017). There is only one isolated case of direct mass spectrometric detection of M. 
tuberculosis free mycolic acids from a Neolithic lesions vertebra (Borowska-Strugińska et 
al., 2014). Mass spectrometry, however, has been the basis of the analysis of ancient 
mycocerosic acids, using selected ion monitoring, negative ion-chemical ionisation GC-MS 
of pentafluorobenzyl ester derivatives (Redman et al., 2009; Lee et al., 2012; Donoghue et 
al., 2017). However, this method is a well-proven procedure, the popularity and availability 
of the necessary instrumentation have declined over the past two decades. Conversely, 
HPLC-MS facilities have become routine in biological and other analytical laboratories. 
However, in our initial analysis the HPLC-MS analysis carried out with a single quadrupole 
analyser was efficient for the detection of the most characteristic MAs of MTBC, its 
sensitivity and specificity was far behind compared to those of achieved with the application 
of Orbitrap MS. 
Finding the proper standards for a method development is always crucial. Unfortunately, to 
purchase commercially available authentic MA standard was not possible from any 
companies represented in Hungary. We were able to start our work with MA standard kindly 
provided by David E. Minnikin. With the help of the provided standard the verification of 
the targeted peaks was carried out with two approaches. Firstly, on the recorded mass 
spectrum beside finding the selected targeted peaks, further MAs have been detected in the 
cases of all the three MA classes. The three MA classes are naturally occurring with at least 
five homologues (Minnikin et al., 2015). Both the targeted and not targeted MAs could be 
included in series of molecules with 28 Dalton differences (two-carbon unit), characteristic 
to the homologous series of MAs, due to their biosynthesis pathway (Takayama et al., 2005). 
With the application of PRM measurements the two most characteristic fragments were the 
365.35767 and the 395.38901, identified as the C24 and C26 α-alkyl chain, respectively. 
These fragments have been observed by other authors (Szewczyk et al., 2013; Song et al., 
2009; Bhamidi et al., 2011; Lehmann et al., 2018).  
During the optimisation procedures with the increased capillary and auxillary gas 
temperature, as well as with the increased capillary and S-lens voltage, the intensity of the 
targeted peaks become higher regardless of the applied solvent composition. The combined 
application of these changes could increase the measured area values with up to 300% in 
some cases. The application of high temperature and capillary voltage was described by 
Szewczyk and colleagues (2013), as well, although the method described by Bhamidi and 
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colleagues (2011) involved the drying gas and vaporiser temperature set only to 300 °C and 
200 °C, however the aim of their study was not the diagnostics, but to reveal a detailed the 
spatial organisation of M. tuberculosis and M. leprae cell wall. 
In contrast with aDNA, obviously there is no option for amplifying the extracted lipid 
biomarkers, thus the efficiency of the extraction is surpassingly important. Overviewing 
several pre-treatment protocols, a very diverse range of descriptions can be found in studies 
covering MA detection methods from sputum and bacterial samples (Hershkovitz et al., 
2008; Song et al., 2009; Bhamidi et al., 2011; Sui et al., 2012; Szewczyk et al., 2013; 
Teramoto et al., 2015; Yoshino et al., 2018). The diversity is partly originated from the 
numerous detection techniques applied for the MA measurements. However, in these 
methods there are some commonly used steps, such as the saponification and the 
acidification before the extraction into the non-polar organic solvent. In our measurements 
first the concentration of KOH in the mixture used during saponification was tested. The 
application of 20% or 30% did not presented any difference, however further decrease to 
10% resulted lower MA outcome. The application of hexane isomer mixture resulted higher 
efficiency regarding the extraction of α- and methoxy-MA specimens, while affected 
negatively the efficiency of the extraction of keto-MAs, hence extraction 3 times with 
toluene was followed by one additional extraction step with hexane. This extraction set up 
seemed to be the most efficient in further comparisons, as well. The results suggested, that 
nonetheless the application of non-polar solvents are needed for the extraction, the lowest 
polarity is not equal with the best efficiency. 
As a reference for later investigations the development of a mycobacterial MA profile library 
has been started, including the profile of MTBC-1/2015, MTBC-254/2000, MTBC-
3910/2014, MTBC-242/2000, MTBC-1/8508/2014, M. gordonae 389/2018, M. 
intracellulare 7802/2017, M. abscessus ssp. abscessus 180/2018, M. kansasii 1959/2018 and 
M. chelonae 16/2018. The α-C78 was found to be the most abundant MA in all the included 
MTBC strains. The second highest representation varied between the α-C80 and m-C85, 
moreover m-C87 was also highly represented. The α-C82, m-C88, k-C87 and m-C89 MAs 
were also represented in higher, than 5% in most of the analysed MTBC strains. Comparing 
our results to those published by Borowska-Strugińska and colleagues (2014) and Bhamidi 
and colleagues (2011) similar distribution patterns were described. Regarding the 
summarised values of individual MA-s based in their type the α-MAs were represented in 
the highest ratio in the involved MTBC strains, ranging between 40%-50%, however in one 
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exception, the highest summarised area values belonged to methoxy-MA specimens, which 
were slightly less represented in the other 4 strains, adding up to approximately 40% of the 
overall area values. The least represented MA type was the keto-MA in every cases. The 
observed distribution of MA classes was very similar to those published by other authors, 
with the application of various methods (Hershkovitz et al., 2008; Bhamidi et al., 2011; 
Szewczyk et al., 2013). The MA profiles of the involved NTM strains draw a more diverse 
picture. Similar to the analysed MTBC strains the most abundant MA specimen was the α-
C78 MA. MAs with higher alkyl-chain and oxygenated MAs were less represented in most 
of NTM strains. In comparison with MTBC the distribution of α-MAs in general was much 
higher in NTM species, than the oxygenated keto- or methoxy-MAs. In our measurements 
the oxygenated MA-s of M. intracellulare, M. abscessus and M. chelonae showed different 
distribution to the published profiles (Minnikin & Brennan, 2020), which implies the need 
of further investigation. However, the published MA profiles of NTM species presents 
differences from our results (Song et al., 2009; Shui et al., 2011; Szewczyk et al., 2013; 
Minnikin & Brennan, 2020), with the low representation of oxygenated mycolates the 
differentiation of MTBC from NTM representatives seems possible with the application of 
lipid profiling via HPLC-MS. 
The application of non-polar solvents is widespread in HPLC-MS based MA detection 
methods, which is most commonly chloroform, but some methods are including hexane due 
to its even lower polarity (Bhamidi et al., 2011; Shui et al., 2012; Szewczyk et al., 2013; 
Borowska-Strugińska et al., 2014; Portevin et al., 2014). In our initial measurements we 
selected the application of chloroform as non-polar component of solvent composition. The 
optimisation to find the best chloroform concentration showed, that the presence and 
increase of chloroform affects negatively the ionisation of MAs on the Orbitrap MS. With 
the application of heptane, as non-polar component we could increase the peak intensity, 
moreover we were able to establish a method for the separation and parallel detection of 
MAs and MCs. Unfortunately, despite of the applied non-polar solvent composition the 
elution of MAs was not complete, especially in the case of MAs with longer alkyl-chain 
length (e.g. k-C86, k-C87). As our aim was to develop a simple, but sensitive method for TB 
diagnostics on archaeological samples, we could not afford even a minimal carry-over during 
our measurements. However, there is a possibility that with further changes on the method 
we could have overcome with this issue, we chose to prioritise working only with MCs, since 
this lipid group is represented in a more limited group of mycobacteria (Redman et al., 2009), 
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and did not show the sign of any carry-over. During the comparison of ESI and APCI as ion 
source, the optimisation of MS parameters for better ionisation of MCs presented similar 
results to those for the detection of MAs, e.g. increased temperature of capillary and auxiliary 
gas and increased capillary and S-lens voltage were beneficial. 
In the development of MC based detection method, a MC profile library was established. 
Among the representatives of MTBC in 4 out of 5 strains the C32 MC was the most 
prominent, while C29 and C30 MCs were present with similar distribution, and C33 MC 
was observed in the lowest ratio, similarly to those detected in the M. tuberculosis H37Rv 
reference strain. The same tendency has been reported with the application of different 
methods (Redman et al., 2009; Lee et al., 2012). The one strain excluded from the 
establishment of the average MC profile of MTB presented a MC distribution more 
characteristic to M. bovis. Among the analysed NTM species (M. avium 16229/2018, M. 
chelonae 16/2018, M. intracellulare 7802/2017, M. fortuitum 3/2018, M. gordonae 
389/2018, M. abscessus sp. abscessus 180/2018, M. chimaera 619/2018, M. kansasii 
1959/2018) only the profile of M. kansasii was established, as the remainder species are not 
expressing mycocerosates. Comparing the chromatograms of MTBC and M. kansasii to the 
observed EICs of the other mycobacteria proved the selectivity of the applied method, as no 
co-eluting peaks were observed, with one exception. The analysed M. avium strain presented 
a peak with the same retention time of C27 MC, which will need further investigation. The 
optimised method seemed to provide an easy and quick way to confirm TB-infected cases 
among archaeological human remains. This hypothesis was tested on samples taken from 
Vác mummies, which were earlier defined TB-positive based on aDNA results. 
In the case of four mummified individuals, profiles of characteristic M. tuberculosis MCs 
were recorded, but two other mummies did not yield diagnostic MC profiles. However, all 
the mummy samples had been found, previously, to be positive by aDNA examination, but 
the samples in this study were not identical with those used previously and the sampling site 
may affect the results. An extended study of confirmed cases, with multiple sampling sites 
of skeletal material and soft tissue, where available, is suggested to clarify the situation. The 
present results, however, provide further confirmation of widespread tuberculosis in the Vác 
mummies. 
The HPLC-ESI-MS method, developed for the detection of MCs, opens up a new avenue for 
the detection of ancient mycobacterial disease, encompassing both tuberculosis and leprosy 
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and joint cases. Currently, the instrumentation required is available in many laboratories and 
technical developments are likely to reduce complexity and increase sensitivity and 
affordability. A particular advantage is that no chemical derivatisation of the particular lipid 
biomarkers is needed, the free acids being utilised. The method could be extended to include 
the related M. tuberculosis lipid biomarker, mycolipenic acid (Donoghue et al., 2017). 
However, in our method we could not overcome with the carry-over of MAs yet, involving 
new solvent compositions and testing new approaches for separation, a comprehensive 
protocol could be developed to add profiles of free mycolic acids. As noted above, free 
mycolic acids were successfully profiled in a Neolithic tuberculosis case (Borowska-
Strugińska et al., 2014) and this study demonstrates the powerful diagnostic capability of 
direct mass spectrometry. In the well-established fluorescence HPLC procedure, the 
recognition of diagnostic mycolate profiles requires extensive derivatisation and sequential 
reverse and normal phase HPLC analyses (Hershkovitz et al., 2008; Donoghue et al., 2017). 
In contrast, in a single selected ion monitoring HPLC run, all the diagnostic mycolic acid 




A történeti korokban előforduló mikobakteriális megbetegségek diagnózisa 
multidiszciplináris megközelítést igényel. A letöbb tuberkulózissal (tbc) összefüggésbe 
hozható csonttani elváltozást a betegség extrapulmonális megjelenési formái eredményezik 
(Aufderheide & Rodríguez-Martín, 1998; Marcsik et al., 1999, 2009; Pálfi & Marcsik, 1999; 
Hershkovitz et al., 2002; Maczel, 2003; Ortner et al., 2003; Paja et al., 2015; Pálfi & Molnár, 
2009; Pálfi et al., 2012; 2015; Mariotti et al., 2015; Spekker, 2018; Spekker et al., 2018; 
Spekker et al., 2020a; Spekker et al., 2020b). A WHO becslései szerint extrapulmonális tbc-
t mindössze az esetek 16%-ában regisztráltak 2019-ben (WHO, 2020). Továbbá az 
egyébként is viszonylag alacsony arányban megjelenő extrapulmonális tbc-s eseteknek csak 
egy kis százalékában alakulnak ki specifikus és detektálható csontelváltozások, ezért a 
makroszkópos paleopatológiai vizsgálatok önmagukban alábecsülik a tbc prevalenciáját a 
történeti embertani anyagok analízise során. A korábban élt népességek között fellelhető tbc-
s esetek számának pontosabb becsléséhez ezért a makroszkópos vizsgálatok mellett, a 
csontokból és lágyszövetekből kivonható, specifikus biomarkerek azonosítására is szükség 
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van, melyek segítségével a morfológiai alapon gyanúsnak ítélt esetek igazolhatók 
(Donoghue et al., 2017). A teljes genom szekvenálás alkalmazásával (Chan et al., 2013), 
olyan új utak nyíltak meg a paleopatológiai vizsgálatokban, melyek segítségével átfogó 
információ nyerhető a fertőzést kiváltó M. tuberculosis törzs típusát és azok számát illetően 
(Bos et al., 2014; Kay et al., 2015). Az aDNS vizsgálatok eredményei jól kiegészíthetők még 
a lipid biomarker profilok vizsgálatával is (Donoghue et al., 2017). Kezdetben a 70-90 
szénatom számú mikolsavak (MA) analízisét vonták be a vizsgálatokba (Gernaey et al., 
1988; Donoghue et al., 1998; Hershkovitz et al., 2008), majd a célzott lipid biomarkerek sora 
a mikocerozátokkal és a C27-es mikolipenáttal (Redman et al., 2009; Lee et al., 2012), 
valamint a phthiocerolokkal bővült (Lee et al., 2012). A mikobakteriális lipid biomarker 
profilok kimutatásához többféle analitikai módszert írtak le (Donoghue et al., 2017). A 
mikolsavak és phthiocerolok kimutatásához első sorban egy jól karakterizált HPLC-FLD 
módszert alkalmaznak a paleopatológiai vizsgálatok során (Hershovitz et al., 2008; Lee et 
al., 2012; Donoghue et al., 2017). Egy esetben találhatunk példát a M. tuberculosis eredetű 
mikolsavak direkt tömegspektrométeres kimutatására (Borowska-Strugińska et al., 2014), 
melyhez a felhasznált minta egy neolit korból származó tbc-vel érintett csigolyából 
származott. A mikocerozát profilon alapuló tbc-diagnosztika a paleopatológiában egy 
gázkromatográfiás elválasztást követő tömegspektrometriás kimutatáson alapul (Redman et 
al., 2009; Lee et al., 2012; Donoghue et al., 2017). Ez a módszer a mikocerozátokat 
pentafluorobenzil észter formában, negatív ion módban kémiai ionizációs eljárással 
vizsgálja. Habár ez az eljárás jól kidolgozott és megfelelően validált, a szükséges műszerek 
egyre kevesebb laboratóriumban elérhetők, miközben a HPLC-MS alkalmazása rutinná vált 
a biológiai és egyéb analitikai alkalmazásokban.  
Bár a munka kezdeti szakaszában, a HPLC-MS vizsgálatok során egy egyszeres quadrupole 
analizátorral a MTBC legkarakterisztikusabb mikolsav típusait sikeresen azonosítottuk, a 
későbbiekben használt Orbitrap MS érzékenysége és specificitása messze meghaladta a 
korábbi műszerét.  
Módszerfejlesztések során elengedhetetlen a megfelelő standard alkalmazása. A 
kereskedelmileg elérhető, autentikus mikolsav standard beszerzése azonban egyetlen 
Magyarországon képviseltetett cégnél sem lehetséges, így munkánkat David E. Minnikin 
által biztosított mikolsav standard felhasználásával kezdtük meg. A standard segítségével a 
detektált csúcsokat két módon azonosítottuk. Elsőként a megfigyelt tömegspektrumon a 
kiválasztott csúcsokon felül további mikolsavakat detektáltunk mind a három mikolsav 
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csoport (alfa-, keto- és metoxi-mikolátok) esetében. Minden mikolsav csoporthoz legalább 
5 homológ mikolsav tartozik (Minnikin et al., 2015), melyek a mért m/z értékeik szerint 
besorolhatók voltak 28 Dalton (két metil-csoport) különbséget mutató sorozatokba. Ez a 
tömegkülönbség a mikolsav homológokra jellemző, azok bioszintézis útvonalát követi 
(Takayama et al., 2005). A mikoslavakat ezután PRM üzemmódban vizsgáltuk, melynek 
segítségével a két legjellemzőbb, mások által is gyakran detektált, az m/z 365.35767 és 
395.38901 fragmenseket azonosítottuk, melyek a C24 és C26 α-alkil láncnak felelnek meg 
(Szewczyk et al., 2013; Song et al., 2009; Bhamidi et al., 2011; Lehmann et al., 2018).  
Az optimalizációs lépések során a kapilláris és a szárítógáz hőmérsékletének, valamint a 
kapilláris és az S-lencse feszültségének növelésével a csúcsok mért intenzitása is emelkedett 
az alkalmazott eluens összetételtől függetlenül. Az említett változtatások alkalmazásával 
néhány esetben az integrált csúcsterület értékek háromszorosukra növekedtek.  Szewczyk és 
munkatársai (2013) szintén magas hőmérsékletet és kapilláris feszültséget alkalmaztak, míg 
Bhamidi és munkatársai (2011) alacsonyabb szárító- (300 °C) és porlasztógáz (200 °C) 
hőmérséklettel dolgoztak, habár fontos megjegyezni, hogy tanulmányuk célja nem 
diagnosztikai jellegű volt, hanem a M. tuberculosis és M. leprae sejtfal térbeli felépítését 
vizsgálták. 
Az aDNS vizsgálatokkal ellentétben természetesen nincs lehetőség a kivont lipid 
biomarkerek felsokszorosítására, így az extrakció hatékonysága kiemelten fontos. A 
mikolsavak vizsgálatával foglalkozó tanulmányok rendkívül változatos mintaelőkészítési 
módszereket alkalmaznak mind a köpet, mind a baktérium minták esetében (Hershkovitz et 
al., 2008; Song et al., 2009; Bhamidi et al., 2011; Sui et al., 2012; Szewczyk et al., 2013; 
Teramoto et al., 2015; Yoshino et al., 2018). A változatosság részben a számos különböző 
MA detektálási technikából ered, azonban ezek a módszerek tartalmaznak néhány 
általánosan előforduló lépést, ilyenek például a szappanosítás, savanyítás és az azt követő 
extrakció apoláris oldószerekkel. Az optimalizálási munka során először a szappanosító 
oldat kálium-hidroxid koncentrációját vizsgáltuk. A 20% és 30% kálium-hidroxidot 
tartalmazó oldatok hatásfoka nem mutatott különbséget, azonban a concentráció 10%-ra 
történő csökkentése negatívan befolyásolta a mikolsav kihozatalt. Az extrakciós oldószerek 
tesztelése során a hexán izomer elegy alkalmazása növelte az alfa- és metoxi-mikolátok 
extrakciójának hatékonyságát, viszont csökkentette a keto-mikolátok kihozatalát, ezért az 
eredetileg alkalmazott három ismétlésben történő toluolos extrakció került kiegészítésre egy 
negyedik, hexános extrakciós lépéssel. További összehasonlítások során szintén ez az eljárás 
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bizonyult a leghatékonyabbnak. Az eredmények alapján úgy tűnik, hogy bár az apoláris 
oldószerek alkalmazása szükséges az extrakcióhoz, ezek alkalmazása nem jelent egyet a 
jobb hatékonysággal.  
A módszer optimalizálása után megkezdtük egy mikobakteriális mikolsav könyvtár építését 
a következő klinikai izolátumok felhasználásával: MTBC-1/2015, MTBC-254/2000, 
MTBC-3910/2014, MTBC-242/2000, MTBC-1/8508/2014, M. gordonae 389/2018, M. 
intracellulare 7802/2017, M. abscessus ssp. abscessus 180/2018, M. kansasii 1959/2018 és 
M. chelonae 16/2018. Az összes MTBC törzs esetében a legnagyobb arányban előforduló 
mikolsav az α-C78 volt. A második legnagyobb mennyiségben előforduló mikolsavak az α-
C80 és a m-C85 voltak, továbbá a m-C87 mikolsav is magas arányban volt jelen. Az α-C82, 
m-C88, k-C87 és a m-C89 mikolsavak magasabb, mint 5%-os arányban fordultak elő. Az 
általunk megfigyelt mikolsav eloszlás a korábban közölt profilokhoz (Borowska-Strugińska 
et al., 2014; Bhamidi et al., 2011) hasonló képet mutatott. Az egyes mikolsavak csúcsterület 
értékeit típusonként is összegeztük, azok egymáshoz viszonyított arányát is vizsgáltuk. Az 
5 klinikai MTBC izolátum vizsgálata során 4 esetben az alfa mikolsavak voltak jelen a 
legnagyobb arányban, mintegy 40%-50%-ban, míg egy törzs esetében a metoxi-mikolátok 
voltak a legnagyobb relatív mennyiségben, melyek a többi törzs esetében az alfa-
mikolsavaknál kisebb arányban, körülbelül 40%-ban voltak jelen. Legkisebb mennyiségben 
a keto-mikolsavakat detektáltuk az összes vizsgált törzsben. A megfigyelt típusonkénti 
mikolsav eloszlás megfelel a más szerzők által leírtaknak, a különböző alkalmazott 
kimutatási módszerektől függetlenül (Hershkovitz et al., 2008; Bhamidi et al., 2011; 
Szewczyk et al., 2013). A nem-tuberkulotikus Mycobacterium fajok mikolsav eloszlása 
sokkal változatosabb képet mutatott. A MTBC törzsekhez hasonlóan, itt is az α-C78 
mikolsav volt jelen a lenagyobb mennyiségben, azonban a hosszabb alkil-lánccal rendelkező 
alfa-mikolátok, valamint a keto- és metoxi-mikolsavak kisebb mennyiségben voltak jelen. 
A MTBC törzsekkel összehasonlítva az alfa-mikolsavak magasabb részarányban jelentek 
meg a keto- és metoxi-mikolátokhoz képest az NTM fajokban. Habár a nem-tuberkulotikus 
Mycobacterium fajok mikolsav profiljait illetően az irodalmi adatoktól eltérő eredményt 
kaptunk a metoxi- és keto-mikolsavak esetében (Song et al., 2009; Shui et al., 2011; 
Szewczyk et al., 2013; Minnikin & Brennan, 2020), azok alacsony arányával a MTBC fajok 




Az apoláris oldószerek használata széles körben elterjedt a HPLC-MS alapú mikolsav 
kimutatási módszerek között, melyek közül leggyakrabban kloroformot, illetve néhány 
esetben a még kevésbé poláris hexánt alkalmazzák eluens összetevőként (Bhamidi et al., 
2011; Shui et al., 2012; Szewczyk et al., 2013; Borowska-Strugińska et al., 2014; Portevin 
et al., 2014). A kezdeti méréseink során mi is a kloroform alkalmazása mellett döntöttünk, 
mint nem poláris eluens komponens. A megfelelő kloroform koncentráció kiválasztására 
irányuló mérések során azonban azt tapasztaltuk, hogy az Orbitrap MS esetében a kloroform 
jelenléte, illetve koncentrációjának növelése negatívan befolyásolja a mikolsavak 
ionizációját. A heptán, mint apoláris eluens összetevő alkalmazásával a detektált csúcsok 
intenzitása növekedett, valamint egy olyan grádiens elúciós módszert tudtunk létrehozni, 
melyben a mikocerozátok és mikolsavak elváltak egymástól, és egyidejűleg vizsgálhatók 
voltak. Annak ellenére, hogy az általunk keresett lipid biomarkerek jól elváltak egymástól, 
az alacsony polaritású eluens elegy ellenére sem volt teljes a mikolsavak elúciója, főként a 
hosszabb alkil-láncú mikolsavak esetén (pl.: k-C86, k-C87). Mivel a célunk az volt, hogy 
egy egyszerű, de érzékeny módszert hozzunk létre, amely a tbc diagnosztikai célú 
paleopatológiai vizsgálataiban alkalmazható, ezért a minták közötti minimális mikolsav 
átszennyezést sem engedtük meg a mérések során. Noha a módszer további változtatásával 
valószínűleg ez a probléma a későbbiekben megoldható lesz, úgy döntöttünk, hogy egylőre 
a mikocerozátok mérését részesítjük előnyben, mivel ezek a lipidek kevesebb 
Mycobacterium fajban vannak jelen (Redman et al., 2009), és egyértelmű választ adnak a 
fertőzés jelenlétére. A mikocerozát kimutatási módszer optimalizálása során az ESI és APCI 
ionforrások kerültek összehasonlításra, valamint az MS paraméterek beállításánál a 
mikolsav módszerben tapasztaltakhoz hasonló eredményre jutottunk (magasabb kapilláris és 
porlasztógáz hőmérséklet, valamint magasabb S-lencse és kapilláris feszültség szintén 
intenzitásnövekedést okozott).  
A mikocerozát alapú kimutatási módszer esetében, szintén egy lipid könyvtár felépítésével 
folytattuk munkát. Az 5 vizsgált klinikai MTBC izolátum közül négyben, illetve a M. 
tuberculosis H37Rv standard törzs esetében a C32-es mikocerozát volt jelen a legnagyobb 
mennyiségben, a C29-es, valamint C30-as mikocerozát egymással közel azonos 
mennyiségben volt kimutatható, míg a legkisebb intenzitást a C27-es és a C33-as 
mikocerozátok mutatták. Az irodalmi adatokban az általunk megfigyelt eloszláshoz hasonló 
eredményekkel találkozhatunk az eltérő módszerek ellenére (Redman et al., 2009; Lee et al., 
2012). Egy klinikai MTBC törzset kizártunk a MTB-ra jellemző átlag mikocerozát eloszlás 
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számításából, mivel annak mikocerozát profilja jobban korrelált a referencia M. bovis törzs 
esetében megfigyeltéhez. A vizsgált NTM fajok közül (M. avium 16229/2018, M. chelonae 
16/2018, M. intracellulare 7802/2017, M. fortuitum 3/2018, M. gordonae 389/2018, M. 
abscessus sp. abscessus 180/2018, M. chimaera 619/2018, M. kansasii 1959/2018) a M. 
kansasii mikocerozát profilja volt megállapítható, mivel a többi vizsgált NTM faj sejtfala 
nem tartalmaz mikocerozátokat. Összehasonlítva a MTBC és M. kansasii extrahált ion 
kromatogramjait a többi vizsgált Mycobacterium fajnál megfigyeltekével a módszer 
szelektivitása bebizonyosodott, valamint egy kivételtől eltekintve nem tapasztaltunk ko-
elúciót más komponensekkel. A vizsgált M. avium törzs esetében a C27-es mikocerozáttal 
megegyező tömegű és retenciós idejű csúcsot detektáltunk, ami további vizsgálatokat tesz 
szükségessé. Az optimalizált módszer alkalmasnak tűnt az archeológiai mintákban a tbc 
fertőzés könnyű és gyors kimutatására. Ennek bizonyítására, a módszert olyan Váci 
múmiákból származó mintákon teszteltük, melyek esetében a tbc fertőzést korábban aDNS 
vizsgálatokkal megállapították.   
A vizsgáltba bevont mumifikálódott egyének közül 4 esetében M. tuberculosis-ra jellemző 
mikocerozát profilt rögzítettünk, míg 2 egyénből származó minták vizsgálata negatív 
eredményt adott. Korábban az összes vizsgált egyén tbc-pozitívnak bizonyult az aDNS 
vizsgálatok alapján, fontos azonban megjegyezni, hogy az általunk vizsgált minták nem 
azonosak a korábban használtakkal és a mintavétel helye erősen befolyásolhatja a 
vizsgálatok eredményét. Egy nagy mintaszámú vizsgálat, melynek során a tbc-pozitív 
egyénekből számos mintavételi hely bevonásával történne szűrés, a későbbiekben segíthetné 
mintavételezéssel járó roncsolás csökkentését, valamint a miénkhez hasonló összehasonlító 
vizsgálatok kivitelezését. A fent említett eltérés ellenére kijelenthető, hogy eredményeink 
további megerősítéssel és adatokkal szolgálnak a Váci múmiák között széles körben elterjedt 
tbc fertőzésről.  
A kifejlesztett HPLC-ESI-MS módszer új utat nyit a mikocerozátok kimutatásában, mellyel 
a mikobakteriális fertőzések a történeti anyagokban is detektálhatók, magában foglalva nem 
csak a tuberkulotikus, de a leprás megbetegedéseket is, illetve azok ko-infekciós 
megjelenését. Napjainkban a kivitelezéshez szükséges műszerezettség sok laboratóriumban 
megtalálható és további technikai fejlesztéssel az eljárás komplexitása és költsége tovább 
csökkenthető, míg érzékenysége növelhető. A módszer nagy előnye, hogy a célzott lipidek 
kimutatása nem igényel kémiai származékképzést, a szabad lipidek önnmagukban 
detektálhatók. A későbbiekben tervezzük a módszer bővítését, a C27-es mikolipenát 
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bevonásával, ami a pentaacil-trehalózok M. tuberculosis-ra jellemző specifikus acil-
összetevője (Donoghue et al., 2017). Bár módszerünkben egyelőre nem oldottuk meg a 
mikolsavak maradéktalan elúcióját, új eluensek és új megközelítési módok bevonásával egy 
átfogó, kombinált módszer létrehozása valószínűnek tűnik. Ahogy a fentebb ismertetett 
példa mutatja egy neolit lelőhelyről származó humán tbc-s eset diagnosztikája kapcsán, a 
szabad mikolsavak direkt HPLC-MS kimutatása egy elérhető megközelítés. A 
paleopatológiában elterjedtebben alkalmazott HPLC-FLD módszer érzékenysége és 
pontossága több ízben bizonyított (Hershkovitz et al., 2008; Donoghue et al., 2017), a 
diagnosztikus mikolsav profil felvételéhez hosszadalmas származékképzési eljárás, valamint 
egymást követő RP- és NP-HPLC elválasztás szükséges. Ezzel ellentétben egy egyszerű 
HPLC-MS módszer alkalmazásával a diagnosztikus mikolsavak detektálása egy gyorsabb 
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